ANNUAL REPORT 2019 unding brave and bold. Cancer. No disease in F the history of medicine has proven more elusive and resilient. It defies logic. It’s unpredictable. It hides in plain sight. It evolves. And it’s soon to be the number one killer in America.

The very nature of cancer is why, at the Damon Runyon Cancer Research Foundation, OUR

we believe that only by pursuing And we support them the and investing in the most best way we know how—with­ audacious and ambitious ideas the money they need to bring will we achieve victory over their ideas from whiteboards humankind’s deadliest enemy. to reality. The funding and freedom to pursue theories, Our research focus is singular: concepts and strategies that high-risk, high-reward. others are not brave or bold enough to bet their careers on. Research that others might deem radical or believe to be Brave and bold. reaching too far. Research that has a good chance of failure, but That’s where the Damon at the same time has a chance to Runyon Cancer Research fundamentally change the game. Foundation invests. That’s where we believe the answers Who does that kind of will come from. research? Brave and bold. Young scientists with the brilliance and unbridled passion The only two words that will to push boundaries and break beat cancer. rules. People with the incredible brainpower to earn millions of dollars on Wall Street or in Silicon Valley, but who have chosen to take a different path, a path that could instead save millions of lives.

2 3 A MESSAGE FROM THE DAMON RUNYON’S NOBEL PRIZE-WINNING SCIENTIFIC PRESIDENT & CEO BREAKTHROUGHS

Discovery of Most recently, we identified a critical area for Quantitative Biology Fellowship Award, to machinery regulating vesicle cancer research: quantitative biology. In this recruit and invest in these people. traffic, a major transport system current era of vast amounts of patient data in our cells (genetic and clinical) and research data, there Earlier this year, we increased our Innovation is an urgent need for scientists with the unique and Clinical Investigator Awards by 33% to provide more robust and much-needed additional resources to our scientists. This Discovery “WE LOOK FOR THE of catalytic new quantitative biology program (described properties Discovery of of RNA the genetic NEXT FRONTIERS, more on page 6) will further increase our principle for generation annual Damon Runyon award programs of antibody AREAS THAT ARE budget to nearly $21.5 million in 2020. We diversity are confident that our sustained investment Discoveries MOST PROMISING AND will lead to even more brave and bold impact concerning the structural YUNG S. LIE, PhD on cancer research. and functional SHOW THE GREATEST organization of the cell POTENTIAL FOR Discoveries concerning the replication BREAKTHROUGHS.” mechanism and Our scientists are brave and bold. They have Discoveries DAMON RUNYON the genetic concerning structure of viruses taken the path less traveled, a path that could hormonal save lives and change medicine forever. expertise to analyze these data in the best way treatment of BOARD MEMBER prostatic cancer possible. What can we learn from these data— As an organization, we also strive to be brave when combined, compared, sorted in the WILLIAM G. KAELIN, and bold. We look for the next frontiers, right ways or perhaps unexpected ways—that JR., MD, WINS 2019 areas that are most promising and show the will inform how to improve cancer treatment, greatest potential for breakthroughs. We diagnosis, and prevention? What are the right NOBEL PRIZE Discovery that seek opportunities to provide funding that types of data to collect in order to explore genes act by regulating Discovery of is catalytic to young innovative scientists, to the ability of important questions in cancer? definite chemical William G. Kaelin, Jr., MD, events poliomyelitis cancer research and to cancer patients. Our viruses to grow in shares the Nobel Prize in cultures of various esteemed scientific leaders work with us to Can we learn more about how cancers types of tissue Physiology or Medicine rigorously evaluate the research landscape, evolve and develop resistance to therapy, Discovery of for discoveries of how cells identifying areas where breakthroughs are or transition from latent to acute disease? co-enzyme A and sense and adapt to oxygen its importance needed and looking for gaps in funding. We To answer these questions, we need for intermediary availability. This work has led metabolism work efficiently and rapidly to design and scientists who are specially trained to work to the development of potential create mechanisms to respond to these needs in quantitative fields (such as mathematics, drugs for heart attack, stroke, anemia and fill these gaps. We ask our current Damon physics, computer science) in addition to and cancer. Dr. Kaelin has shown Runyon scientists to help us brainstorm other cancer biology. For these reasons, we are incredible dedication to the leadership Preparation of enzymes and virus ways we can support their career trajectory proud and excited to announce that we have of the Foundation’s scientific programs, proteins in a pure form and success, and accelerate their progress. created a new program, the Damon Runyon particularly the Clinical Investigator and Physician-Scientist Training Awards. Discovery of the chemical nature of vitamin K Discoveries in connection with the biological combustion processes

4 5 e are at a unique time in cancer QUANTITATIVE research, when the volume and W diversity of data—including genome sequences, catalogs of all the proteins in a single cell and patient information such as pathology and imaging —is exponentially growing. Increasingly, biologists are required to not only work at the lab bench, but also mine vast amounts of data to find the valuable clues that will address key challenges in cancer research and patient treatment.

Damon Runyon anticipates the need for an elite cadre of computational biology INAUGURAL AWARD leaders with expertise and understanding in both quantitative and biological sciences—scientists who are capable of traversing both worlds with ease and

BIOLOGY “BECAUSE THIS IS MEET AVIV REGEV, PhD IN ESSENCE A NEW The Foundation is thrilled to have one of the world’s most accomplished FIELD...IT IS CRITICAL computational biologists, Aviv Regev, PhD, lead the selection committee for TO DRAW FEARLESS the new Damon Runyon Quantitative Biology Fellowship Award. “She AND BRILLIANT has a proven track record of using quantitative tools to drive major discoveries in cancer,” says Todd R. 2020 YOUNG SCIENTISTS Golub, MD, of the Broad Institute, and Damon Runyon Board Member. TO THESE PROBLEMS Dr. Regev, also of the Broad Institute, has pioneered many leading TO DRIVE THE FIELD experimental and computational methods that are now widely used FORWARD.” by her colleagues in the field. She is AVIV REGEV, PhD co-leading one of the most ambitious projects in the history of biology—the FELLOWSHIP are truly bilingual, comfortably speaking Human Cell Atlas—which is creating both languages fluently. Highly skilled a reference map that categorizes the quantitative scientists, however, may be approximately 37 trillion cells that comprise the human body.

6 7 QUANTITATIVE BIOLOGY FELLOWSHIP AWARD

Q&A WITH DR. AVIV REGEV

pulled toward the technology industry The Damon Runyon Quantitative Biology WHAT IMPACT DO to create the next Google, Amazon or Fellowship Award will support a new YOU HOPE THE AWARD YouTube. To proactively address this generation of computational scientists who WILL HAVE IN THE need, Damon Runyon has created a new will pioneer novel approaches to the design DR: WHY IS THIS AWARD SHORT-TERM? AND WHY IS DAMON funding mechanism designed to encourage and interpretation of experiments in cancer SO IMPORTANT AT THIS IN THE LONG-TERM? RUNYON THE RIGHT quantitative scientists (trained in fields such research, to answer a myriad of important PARTICULAR TIME IN ORGANIZATION TO In the short-term, as mathematics, physics, computer science, biological and clinical questions. CANCER RESEARCH? BE LAUNCHING THIS empowering trailblazing engineering and others) to pursue research AWARD? young scientists in this careers in computational biology. “Damon Runyon is well-positioned to launch Dr. Regev: The vast amount such an ambitious and bold endeavor. of data being collected area will impact our ability Damon Runyon has long We must ensure that the presents a remarkable to predict and understand been at the very forefront cancer research field has opportunity to connect all disease and find therapeutic of training generations of strong leadership at the aspects of cancer biology targets. In the mid-term, the scientists in pursuing bold intersection of cancer in human patients and in scientists trained through new approaches to cancer biology and computational animal models that are both these awards will be part of research. It is mission-driven science. The Foundation has predictive and mechanistic. a new cadre of leaders to and can ensure the focus a long history of identifying This will not only drive drive the field forward. And and drive in this critical area. visionary, early career cancer research forward, but in the long-term, it will make scientists and investing in will also unveil new clinically it possible to bring new them,” says Todd R. Golub, relevant insights that will data-driven and machine MD, of the Broad Institute, ultimately impact patient learning approaches to and Damon Runyon Board care. However, it also poses cancer research beyond the Member. a large analysis challenge, lab and into the clinic. and requires deep expertise Exposing more cancer not just in applying researchers and oncologists current methods but also to data science, and in inventing new ones. computational scientists “DAMON RUNYON IS Fortunately, the remarkable to the biological complexity of cancer are “Because this is in essence a new field at advances in data science and critical steps to finding cures. “Realizing WELL-POSITIONED the nexus of traditional cancer research and machine learning of the past the importance of the burgeoning field of data science, it is critical to draw fearless and decade should be up to this quantitative cancer biology, Damon Runyon TO LAUNCH SUCH AN brilliant young computational scientists to challenge. We need to bring is clearly signaling the importance of this these problems to drive the field forward,” experts in these fields in full area for the future of cancer research,” AMBITIOUS AND BOLD says Aviv Regev, PhD, of the Broad Institute force into cancer research. and inaugural Chair of the new Quantitative says Dr. Regev. ENDEAVOR.” Biology Fellowship Award Committee. TODD R. GOLUB, MD

8 9 SCIENTIST SPOTLIGHT SAKIKO SUZUKI, MD STRIVING FOR BREAKTHROUGH TREATMENTS

10 11 SCIENTIST SPOTLIGHT

SAKIKO SUZUKI, MD going to be available to treat your cancer.” I can say that with more authenticity since IN THE BEST POSSIBLE I’m in the laboratory doing SCENARIO, HOW WOULD research, than I could when I YOUR WORK IMPACT PHYSICIAN-SCIENTIST DR: WHAT IS THE inflammation causing the was just a clinician. CANCER PATIENTS? Inflammation and Cell Death CURRENT STATE OF cell death that causes more WHAT HAS DAMON YOUR DAMON RUNYON- inflammation. If we can just INSTITUTION RUNYON’S SUPPORT I’m trying to prevent MDS University of Massachusetts FUNDED RESEARCH? interrupt that cycle, there MEANT TO YOUR patients from progressing Medical School might be a way of treating into the leukemia stage these debilitating conditions. CAREER? PROJECT TITLE amon Runyon Sakiko: We’re trying where they need more “Inflammatory cell death to determine whether serious chemotherapy and Physician-Scientist HOW DOES YOUR I can tell you with 100% pathways in Myelodysplastic Sakiko Suzuki, inflammation and stem cell or bone marrow Syndromes” D INTERACTION WITH certainty that if I didn’t have inflammatory cell death drive transplant. If we can diagnose MD, at the University of CANCER PATIENTS the Damon Runyon support, I Myelodysplastic Syndrome the pre-cancerous conditions Massachusetts Medical AFFECT YOUR would be a full-time physician (MDS), a type of cancer and nip it in the bud, we School, combines a RESEARCH, AND VICE with research a very remote caused by abnormal bone are saving patients side deep commitment to her VERSA? part of my life. The only marrow cells that have effects, painful recovery and patients with a passion for reason I’m able to work in the difficulty making new blood expensive treatments. discovery. Sakiko focuses In the clinic, I treat patients lab right now, continuing my cells. As a result, many of on hematologic (blood) with leukemia and lymphoma scientific training, is because the blood cells produced cancers. Trained as an and often they get bone of Damon Runyon. There was are defective and often engineer, she once worked marrow transplants, which no other funding. die earlier than normal on engineering systems to provide a chance of a cure. In the meantime, we need to “IF WE CAN JUST INTERRUPT [THE] deal with the complications that come from these CYCLE, THERE MIGHT BE A NEW WAY treatments. In the lab, we are working on treatments OF TREATING THESE CONDITIONS.” that may be years away from clinical application but have the potential to cure patients. cells, leaving the person help thousands of people at I can take that excitement without enough healthy a time. “As a physician, you of future breakthroughs blood cells. We’ve known help one person at a time. to patients who might be for decades that MDS But as a physician-scientist, losing hope and say, “Hang patients have bone marrow I’m inching back towards in there—in three years, who and blood characterized that engineering side where knows what treatments are my research can help many by signs of inflammation. people with one project.” But is inflammation causing the disease, or is the disease process causing the inflammation? I believe MDS BLOOD CELLS it’s a vicious cycle with Abnormal blood cells (dark purple) from a myelodysplastic (MDS) patient. MDS is caused MYELOID CELLS by poorly formed blood cells that do not work properly. This Immature myeloid cells in the blood failure of the bone marrow (pictured) fail to work properly and cause often progresses to acute symptoms such as fatigue, pain, recurrent myeloid leukemia (AML). and prolonged infections, and bruising.

12 13 SCIENTIST SPOTLIGHT

“BEFORE EMBARKING ON BENJAMIN L. MARTIN, Ph D THIS PROJECT, WE KEPT DAVID Q. MATUS, Ph D

HEARING, ‘THIS DOESN’T INNOVATORS Cell Biology of Metastasis

HAPPEN IN CANCER.’” INSTITUTION Stony Brook University DAVID Q. MATUS, PhD PROJECT TITLE “Cell cycle regulation of cellular behaviors associated with cancer metastasis”

VISUALIZING THE The researchers are proving block metastasis. “Most cancer DEADLY SPREAD they have the right idea. Using therapeutic strategies are not OF CANCER state-of-the-art microscopy geared towards eliminating and genetic analysis, they have dormant tumor cells that ancer is synonymous achieved an unprecedented may evade standard first-line with uncontrolled cell level of understanding about therapies,” Benjamin explains. C division. It makes sense, how circulating tumor cells exit “As we make progress, it’s then, that many drugs target blood vessels and invade new opening up new questions and actively dividing cells to stop sites in the body. “The great different directions that our labs tumor growth. But Damon strength of our collaboration is are pursuing.” Runyon-Rachleff Innovators approaching the problem using Benjamin L. Martin, PhD, different model organisms and David Q. Matus, PhD, at [zebrafish and roundworm],” Stony Brook University, have says Benjamin. taken a daring new approach that addresses recurrence They have captured the and metastasis, the spread movement of human breast David and ZEBRAFISH of cancer cells to distant cancer cells injected into the Benjamin organs. “We think of cancer vascular system of the zebrafish exemplify Damon Runyon’s progression as increases in both in high-resolution 3D video. focus on finding creative, uncontrolled proliferation and It is the first time the process bold thinkers willing to push invasive behavior,” David says. has been recorded live, in the boundaries of established stunning detail—the cell rolling, science. Both credit Damon Their research stems from crawling, and moving out of a Runyon with providing support David’s discovery in the blood vessel. at a critical juncture in their roundworm C. elegans that research. Since the Damon cells cannot simultaneously In parallel, they have identified Runyon award, “we have divide and invade. “People the molecular control switch received additional funding didn’t think that cells needed that causes cells to stop dividing from other sources that we may to stop dividing before and increases their capacity to not have—just based on the invading. We kept invade other tissue. novelty and risk of our original hearing that this Insights from their idea,” says Benjamin. “That was doesn’t happen work may lead to an initial huge impact for both in cancer,” the development of us.” David says. of new drugs to

CAENORHABDITIS ELEGANS (C. ELEGANS)

14 15 SCIENTIST SPOTLIGHT KYLE G. DANIELS, Ph D PIONEERING KILLER CAR T THERAPIES

16 17 SCIENTIST SPOTLIGHT KYLE G. DANIELS, Ph D

FELLOW Synthetic Immunology

INSTITUTION University of California, San Francisco

PROJECT TITLE SEQUENCING DATA “Controlling T cell signaling and fate choice using Sequencing data synthetic receptors” AR (chimeric antigen It’s a bold move. Most (pictured) shows the precise order of receptor) T cell scientists who study CAR bases—A, C, G, T—in C therapy outsmarts T cells are making small, a given DNA molecule. cancer by using a patient’s “T cells act like little ‘decision- incremental changes to one Buried within the own immune system, and making robots,’ which can CAR T type. “My project is effective over time. “Already thousands of letters are it is saving lives—in some be reprogrammed to strike ambitious. We decided to we’ve found cell signals that clues to creating CAR T cells that are more cases when all else has failed. against a specific cancer— look at thousands of CARs at give us three or four times effective in treating These engineered T cells are it’s a much more intelligent once with diverse properties as many memory cells as the patients. removed from the cancer therapeutic approach,” says to find what makes the most treatments that are on the patient, genetically tailored Damon Runyon Fellow Kyle G. effective CAR Ts,” Kyle market now,” he says.

in the lab to recognize that Daniels, PhD, at the University explains. The volume of data patient’s individual cancer, of California, San Francisco. he is collecting makes this Looking back four years ago, and then injected back First-generation CAR T cells particularly challenging. He is Kyle remembers turning down into the body to find and have proved effective only for creating the tools to visualize another prestigious award to kill tumor cells. Unlike a a small number of patients complex, multi-dimensional accept the Damon Runyon traditional small molecule with lymphoma and leukemia. data sets and extract Fellowship. “When you meet drug with a temporary Kyle is creating a sleek meaningful information. another scientist in the field, effect, CAR T therapy is a redesign that will give CAR living drug given once that, T cells superior anticancer “I WANTED TO HAVE A MORE IMMEDIATE theoretically, can protect the abilities to work more body for life. efficiently with fewer side effects, for more patients. IMPACT ON PEOPLE’S LIVES, AND THIS IS “I wanted to have a more immediate impact on people’s PROBABLY ABOUT AS CLOSE AS A BASIC lives, and this is probably about as close as a basic SCIENTIST CAN GET TO THAT.” CAR T CELL scientist can get to that.” Buried within these data are they know Damon Runyon, and CAR T treatment involves genetically tailoring a patient’s clues to creating CAR T cells it automatically gives you a bit T cells to specifically find and kill that divide more rapidly once of cancer ‘street cred.’ Having the individual’s tumor cells. re-injected into the body, for the time and private support a stronger upfront response from Damon Runyon has given to the cancer, and last longer me the freedom to trust my gut so that the therapy is more and follow my instincts.”

18 19 SCIENTIST SPOTLIGHT “DESPITE THE INITIAL FAILURE AMAIA LUJAMBIO, PhD ...I HAD A GUT FEELING THAT IT INNOVATOR WOULD EVENTUALLY WORK.” Resistance to Immunotherapy

INSTITUTION Icahn School of Medicine at Mount Sinai

PROJECT TITLE “Overcoming resistance to anti-PD1 immunotherapy in hepatocellular carcinoma”

TRAVERSING UNCHARTED DR: HOW IS YOUR HOW HAS DAMON RUNYON TERRITORY FOR CURES RESEARCH ADDRESSING BOOSTED YOUR CAREER IN SOME OF THE DIFFICULTIES UNEXPECTED WAYS? For Damon Runyon-Rachleff CHECKPOINT INHIBITOR Innovator Amaia Lujambio, PhD, Receiving a Damon Runyon THERAPY FACES IN THE at the Icahn School of Medicine award is very prestigious and CLINIC? at Mount Sinai, cancer research highly competitive. It has given isn’t just a job, it’s a passion. Amaia: We are working on me a lot of visibility and a broad Amaia decided to focus on identifying which patients network that has been critical to hepatocellular carcinoma (HCC), are more likely to respond establishing collaborations. the most common form of liver to therapy and trying to cancer, because she wanted to establish novel combinations I met Dr. Joshua Brody, a Damon tackle a difficult disease with of immunotherapies that can Runyon Clinical Investigator, who few treatment options and poor be effective in those patients also works at Mount Sinai, at a prognosis. Patients who cannot that are initially resistant to Damon Runyon retreat. We decided have surgery on their tumors immunotherapy. to join forces by adapting his novel have a median survival of less therapies for lymphoma to liver than a year. Trying to understand what’s cancer. I have another exciting going on inside patients is collaboration with scientists at “Despite the initial failure complicated by the different Genentech in San Francisco, who of checkpoint inhibitor mutations each person’s are developing novel combination immunotherapies in clinical tumor carries. We created a immunotherapies for liver cancer trials for liver cancer patients, I mouse model that accurately patients. had a gut feeling that it would resembles tumors in patients. eventually work,” Amaia says. Using this model and samples IS YOUR DAMON RUNYON from HCC patients treated RESEARCH PROPOSAL RISKY? She was right. Now that with checkpoint inhibitor, we Yes. That’s why I decided to apply immunotherapy has been recently found a pathway that for the Damon Runyon Innovation approved for liver cancer promotes immune escape Award—because it specifically patients, her lab is focusing on and drug resistance. These funds high-risk, high-reward deciphering why only a small findings will be critical in projects. The basis of the project subset of patients respond to defining biomarkers to select was innovative, but we didn’t these treatments and finding the HCC patients that are have enough preliminary data for strategies to overcome resistance. most likely to benefit and help conventional funding agencies. design strategies to overcome Damon Runyon sat down with resistance. We have already published part Amaia to learn more about her of our new data in a high-impact bold foray into the frontiers of journal, so now I feel confident that immunotherapy for liver cancer. the risk was definitely worth it.

20 21 DAMON RUNYON CANCER RESEARCH FOUNDATION Gabrielle Layton, PhD Andrew S. Rachleff Nat Turner PALO ALTO, CALIFORNIA Chairman and Chief Co-Founder and Chief Executive Officer Executive Officer BOARD OF DIRECTORS David M. Livingston, MD Wealthfront Inc. Flatiron Health Emil Frei Distinguished PALO ALTO, CALIFORNIA NEW YORK, NEW YORK Professor of Genetics and Medicine William M. Raveis, Jr. Peter Van Camp Harvard Medical School and Chairman and Chief Executive Chairman Dana-Farber Cancer Institute Executive Officer Equinix, Inc. VICE CHAIR VICE CHAIR BOSTON, MASSACHUSETTS William Raveis Real Estate, REDWOOD CITY, CALIFORNIA Scientific Programs Board Development Mortgage & Insurance William G. Kaelin, Jr., MD Michael L. Gordon David G. Marshall SOUTHPORT, CONNECTICUT James A. Wells, PhD Sidney Farber Professor Chief Executive Officer Chairman and Chief Harry Wm. and Diana V. Hind of Medicine and Co-Chief Investment Executive Officer Michael V. Seiden, MD, PhD Distinguished Professor in Dana-Farber Cancer Institute Officer Amerimar Realty Company President Pharmaceutical Sciences and Harvard Medical School Angelo Gordon PHILADELPHIA, PENNSYLVANIA The US Oncology Network Professor, Molecular and Howard Hughes Medical NEW YORK, NEW YORK THE WOODLANDS, TEXAS Cellular Pharmacology Institute Investigator John H. Myers University of California, BOSTON, MASSACHUSETTS VICE CHAIR Director Karen D. Seitz San Francisco David M. Beirne Academy Securities Founder and Managing Director SAN FRANCISCO, CALIFORNIA VICE CHAIR CHAIR General Partner FAIRFIELD, CONNECTICUT Fusion Partners Global LLC Investments and Treasurer X10 Capital Alan M. Leventhal NEW YORK, NEW YORK Leon G. Cooperman SAN FRANCISCO, CALIFORNIA Chairman and Chief Richard J. O’Reilly, MD Yung S. Lie, PhD Chairman and Chief Claire L. Tow Chair, Pediatric Executive Officer VICE CHAIR Nancy Simonian, MD President and Chief Executive Officer Oncology Research Beacon Capital Partners, LLC Deborah J. Coleman Chief Executive Officer Executive Officer Omega Operating, LLC Memorial Sloan Kettering BOSTON, MASSACHUSETTS Legal Counsel Syros Pharmaceuticals, Inc. Damon Runyon Cancer NEW YORK, NEW YORK Cancer Center CAMBRIDGE, MASSACHUSETTS Convexity Capital Research Foundation NEW YORK, NEW YORK VICE CHAIR Management LP Cynthia F. Sulzberger Lorraine W. Egan Audit and Secretary BOSTON, MASSACHUSETTS WELLINGTON, FLORIDA President and Chief Sanford W. Morhouse, Esq. Executive Officer (retired) Of Counsel Judy C. Swanson Damon Runyon Cancer Schulte Roth & Zabel LLP HILLSBOROUGH, CALIFORNIA Research Foundation NEW YORK, NEW YORK

EMERITUS MEMBERS

Steven J. Burakoff, MD Elaine V. Fuchs, PhD Scott Greenstein Sidney Altman, PhD Connie Lurie Samuel C. Silverstein, MD Dean for Cancer Innovation, Laboratory Head, Laboratory President and Chief Content Professor Emeritus, Molecular, ATHERTON, CALIFORNIA John C. Dalton Professor The Tisch Cancer Institute of Mammalian Cell Biology Officer Cellular and Developmental of Physiology and Cellular Chief, Division of Pediatric and Development SiriusXM Biology and Chemistry I. George Miller, Jr., MD Biophysics Hematology and Oncology Rebecca C. Lancefield NEW YORK, NEW YORK Senior Research Scientist, John F. Enders Professor Professor, Medicine Lillian and Henry M. Stratton Professor Molecular, Cellular and of Pediatrics Columbia University College of Professor of Cancer Medicine The Rockefeller University Steve Hayden Developmental Biology Professor, Epidemiology, and Physicians and Surgeons Icahn School of Medicine at Howard Hughes Medical Vice Chairman and Chief Yale University Molecular Biophysics and NEW YORK, NEW YORK Mount Sinai Institute Investigator Creative Officer (retired) NEW HAVEN, CONNECTICUT Biochemistry NEW YORK, NEW YORK NEW YORK, NEW YORK Ogilvy & Mather Worldwide Section Chief, Pediatric Craig B. Thompson, MD NEW YORK, NEW YORK David Baltimore, PhD Infectious Diseases President and Chief Robyn Coles Richard B. Gaynor, MD President Emeritus Yale School of Public Health Executive Officer President President of Research Jay W. Ireland Robert Andrews Millikan NEW HAVEN, CONNECTICUT Memorial Sloan Kettering TRATE Properties, LLC and Development President and Chief Executive Professor of Biology Cancer Center BOSTON, MASSACHUSETTS Neon Therapeutics Officer (retired) California Institute of Henry C. Pitot, MD, PhD NEW YORK, NEW YORK CAMBRIDGE, MASSACHUSETTS General Electric Africa Technology Professor Emeritus, Oncology, Gary E. Erlbaum NEW YORK, NEW YORK PASADENA, CALIFORNIA Pathology and Laboratory Virginia Ueberroth President Todd R. Golub, MD Medicine, McArdle Laboratory Chairman Greentree Properties Chief Scientific Officer Morana Jovan-Embiricos, PhD Kenneth G. Langone for Cancer Research The Ueberroth Family ARDMORE, PENNSYLVANIA and Director, Cancer Program Managing Partner Chairman and Chief University of Wisconsin School Foundation Broad Institute of MIT F2 Capital Ventures LLP Executive Officer of Medicine and Public Health CORONA DEL MAR, CALIFORNIA Thomas J. Fahey, Jr., MD and Harvard LONDON, UNITED KINGDOM Invemed Associates, LLC MADISON, WISCONSIN Senior Vice President Emeritus Charles A. Dana Investigator NEW YORK, NEW YORK Robert C. Wright Memorial Sloan Kettering in Human Cancer Genetics Steven A. Kandarian Katharine F. Plum Senior Advisor Cancer Center Dana-Farber Cancer Institute Chairman, President and Chief Ronald Levy, MD HOBE SOUND, FLORIDA Lee Equity Partners, LLC NEW YORK, NEW YORK Professor, Pediatrics Executive Officer (retired) Robert K. and Helen K. Summy NEW YORK, NEW YORK Harvard Medical School MetLife, Inc. Professor Buck French Howard Hughes Medical NEW YORK, NEW YORK Stanford University School Robert C. Young, MD General Partner Institute Investigator of Medicine Former Chancellor X10 Capital CAMBRIDGE, MASSACHUSETTS Noah Knauf STANFORD, CALIFORNIA Fox Chase Cancer Center SAN FRANCISCO, CALIFORNIA General Partner President Bond Capital RCY Medicine SAN FRANCISCO, CALIFORNIA PHILADELPHIA, PENNSYLVANIA

22 23 BAY AREA COMMITTEE AWARD

Ronald A. Castellino, MD Connie Lurie Judy C. Swanson* Professor Emeritus, Radiology, ATHERTON, CALIFORNIA HILLSBOROUGH, CALIFORNIA Academic Council PROGRAMS Stanford Medicine Carole Middleton Polly Tam WOODSIDE, CALIFORNIA HILLSBOROUGH, CALIFORNIA LOS ALTOS HILLS, CALIFORNIA In FY2019, Damon Runyon awarded nearly Carson Eltoukhy Andrew S. Rachleff* Peter Van Camp* ATHERTON, CALIFORNIA Chairman and Chief Executive Chairman $20M to 66 newly selected, exceptional scientists. Executive Officer Equinix, Inc. Buck French* Wealthfront Inc. REDWOOD CITY, CALIFORNIA General Partner PALO ALTO, CALIFORNIA X10 Capital James A. Wells, PhD* SAN FRANCISCO, CALIFORNIA Isabel Rhee Harry Wm. and Diana V. Hind DAMON RUNYON FELLOWSHIP AWARD DAMON RUNYON PHYSICIAN- LOS ALTOS, CALIFORNIA Distinguished Professor in SCIENTIST TRAINING AWARD Noah Knauf* Pharmaceutical Sciences Supports the training of the brightest General Partner Gordon M. Ringold, PhD Professor, Molecular and postdoctoral scientists as they embark Supports and encourages outstanding Bond Capital Chief Executive Officer Cellular Pharmacology SAN FRANCISCO, CALIFORNIA Quadriga Biosciences University of California, upon their research careers. This funding recent medical school graduates to PALO ALTO, CALIFORNIA San Francisco enables them to be mentored by established pursue cancer research careers by funding Brigette Lau SAN FRANCISCO, CALIFORNIA investigators in leading research laboratories a protected research training experience Partner Karen D. Seitz* Social Capital LP Founder and Managing Director across the country. under the guidance of a highly qualified PALO ALTO, CALIFORNIA Fusion Partners Global LLC and gifted mentor. NEW YORK, NEW YORK FOUR-YEAR AWARD: $231,000 Gabrielle Layton, PhD* plus up to $100,000 for medical school loan repayment PALO ALTO, CALIFORNIA *Indicates member is FOUR-YEAR AWARD: $460,000 also a Board Member plus up to $100,000 for medical school loan repayment

DAMON RUNYON-SOHN PEDIATRIC CANCER FELLOWSHIP AWARD DAMON RUNYON CLINICAL INVESTIGATOR AWARD Supports dedicated basic scientists and NEW YORK METRO COMMITTEE clinicians who conduct research with Supports early career physician-scientists the potential to significantly impact the conducting patient-oriented research. This Kathy Braddock Gerald M. Marshall Paul Purcell prevention, diagnosis or treatment of innovative program aims to increase the Managing Director Co-Chairman and Chief Managing Director one or more pediatric cancers. William Raveis New York City Executive Officer William Raveis New York City number of physicians who can seamlessly NEW YORK, NEW YORK Amerimar Enterprises, Inc. NEW YORK, NEW YORK move between the laboratory and the patient’s President and Chief FOUR-YEAR AWARD: $231,000 bedside in search of breakthrough treatments. Melissa L. Cohn Executive Officer Karen D. Seitz* plus up to $100,000 for medical school loan repayment Executive Vice President of the Netrality Properties Founder and Managing Director Private Client Group NEW YORK, NEW YORK Fusion Partners Global LLC THREE-YEAR AWARD: $600,000 Family First Funding NEW YORK, NEW YORK plus up to $100,000 for medical school loan repayment DAMON RUNYON-DALE F. FREY AWARD NEW YORK, NEW YORK Joseph R. Osborne, MD, PhD and the possibility of an additional $400,000 extension Chief, Nuclear Medicine and FOR BREAKTHROUGH SCIENTISTS over two years Robyn Coles* Molecular Imaging President Director, Molecular Imaging Supports a select few Damon Runyon Fellows TRATE Properties, LLC Innovations Institute who have exceeded the Foundation’s highest DAMON RUNYON-RACHLEFF BOSTON, MASSACHUSETTS Associate Professor, Radiology New York-Presbyterian expectations. This additional investment in INNOVATION AWARD Erica Evans Gioffre Hospital/Weill Cornell these exceptional individuals catapults their Head, Client Engagement Medicine research careers and their impact on cancer. Supports the next generation of exceptionally Hirtle, Callaghan & Co. NEW YORK, NEW YORK creative thinkers with high-risk, high-reward WEST CONSHOHOCKEN, *Indicates member is PENNSYLVANIA also a Board Member TWO-YEAR AWARD: $100,000 ideas that have the potential to significantly impact our understanding of and approaches to the prevention, diagnosis or treatment of cancer.

TWO-YEAR AWARD: $400,000 with the possibility of an additional $400,000 extension over two years

24 Annual Report 2019 25 DAMON RUNYON FELLOWSHIP AWARD COMMITTEE

CHAIR Lucy A. Godley, MD, PhD Lynne E. Maquat, PhD Aaron F. Straight, PhD Matthew G. Vander Heiden, Amy J. Wagers, PhD Co-Director, Center for Clinical J. Lowell Orbison Endowed Associate Professor, MD, PhD Co-Chair and Forst Family Rachel Green, PhD Cancer Genetics Chair and Professor, Biochemistry Eisen and Chang Associate Professor of Stem Cell and Bloomberg Distinguished Professor, Medicine, Section of Biochemistry and Biophysics, Stanford University Professor and Associate Regenerative Biology Professor, Molecular Hematology and Oncology School of Medicine and School of Medicine Director Harvard University Biology and Genetics The University of Chicago Dentistry STANFORD, CALIFORNIA Koch Institute for Integrative Senior Investigator Johns Hopkins School Medicine Director, Center for Cancer Research at MIT Joslin Diabetes Center of Medicine CHICAGO, ILLINOIS RNA Biology Jessica Tyler, PhD Instructor of Medicine Harvard Medical School Howard Hughes Medical University of Rochester Professor, Pathology and Dana-Farber Cancer Institute CAMBRIDGE, MASSACHUSETTS Institute Investigator Richard I. Gregory, PhD Medical Center Laboratory Medicine and Harvard Medical School BALTIMORE, MARYLAND Professor, Biological Chemistry ROCHESTER, NEW YORK Weill Cornell Medicine Member and Molecular Pharmacology, VICE CHAIR NEW YORK, NEW YORK Broad Institute Department of Pediatrics Joel H. Rothman, PhD CAMBRIDGE, MASSACHUSETTS Greg Barton, PhD Harvard Medical School and Professor and Wilcox Family Class of ’36 Endowed Chair, Harvard Stem Cell Institute Chair in Biotechnology Department of Molecular Principal Investigator University of California, and Cell Biology Boston Children’s Hospital Santa Barbara SANTA BARBARA, CALIFORNIA Professor, Immunology BOSTON, MASSACHUSETTS DAMON RUNYON and Pathogenesis University of California, Howard C. Hang, PhD Davide Ruggero, PhD Berkeley Richard E. Salomon Family Professor and Helen Diller BERKELEY, CALIFORNIA Associate Professor, Family Endowed Chair in Laboratory of Chemical Basic Research FELLOWSHIP AWARD Martin D. Burke, MD, PhD Biology and Microbial University of California Professor, Chemistry Pathogenesis San Francisco School University of Illinois at The Rockefeller University of Medicine Urbana-Champaign NEW YORK, NEW YORK Member, UCSF Comprehensive Associate Dean of Research Cancer Center Jay Hesselberth, PhD Carle Illinois College SAN FRANCISCO, CALIFORNIA California Ryan A. Flynn, MD, PhD Associate Professor, Scripps Research Institute of Medicine The interplay between Biochemistry and Molecular Susan R. Schwab, PhD CHAMPAIGN, ILLINOIS California Institute of Technology Marsha M. Hirschi, PhD cellular metabolism and RNA Genetics Associate Professor, Pathology, Dennis and Marsha homeostasis in disease with University of Colorado Skirball Institute of Ariana Peck, PhD* Jayanta Chaudhuri, PhD Dammerman Fellow Carolyn R. Bertozzi, PhD Professor, Immunology School of Medicine Biomolecular Medicine The Mark Foundation for Molecular engineering AURORA, COLORADO New York University School Cancer Research Fellow Program of an optically controlled Christina L. Hueschen, PhD* Memorial Sloan Kettering of Medicine Expanding the reach of glutamate receptor with E. Jane Albert Hubbard, PhD Molecular basis and regulation Cancer Center NEW YORK, NEW YORK structure determination with Gabriel C. Lander, PhD Professor, Cell Biology and nanocrystal tomography with of apicomplexan parasite NEW YORK, NEW YORK motility with Alex Dunn, PhD Pathology, Skirball Institute of M. Celeste Simon, PhD Grant J. Jensen, PhD Xiaoyu Zhang, PhD Biomolecular Medicine Scientific Director and Discovery of chemical probes Jennifer L. Gerton, PhD Victoria Hung, PhD New York University School Investigator, Abramson Family that support targeted protein Professor, Biochemistry Salk Institute Fraternal Order of of Medicine Cancer Research Institute degradation in human cancer and Molecular Biology Eagles Fellow NEW YORK, NEW YORK Associate Director, Abramson Corina E. Antal, PhD with Benjamin F. Cravatt, PhD The University of Kansas Defining the post-translational School of Medicine Cancer Center Core Facilities Robert Black Fellow Susan M. Kaech, PhD landscape of ribosomes in Investigator Arthur H. Rubenstein, Stromal reprogramming as Professor and Director, NOMIS Stanford University control of gene regulation and Stowers Institute for MBBCh Professor, Cell and a therapeutic approach in Center for Immunobiology and cell fate with Maria Barna, PhD Medical Research Developmental Biology pancreatic cancer with Christopher J. Cambier, PhD Microbial Studies University of Pennsylvania Ronald M. Evans, PhD HHMI Fellow KANSAS CITY, MISSOURI John C. Janetzko, PhD NOMIS Chair Perelman School of Medicine In vivo characterization of A biophysical approach to Antonio J. Giraldez, PhD Salk Institute for Biological PHILADELPHIA, PENNSYLVANIA Hokyung K. Chung, PhD* mycobacterial cording with studying GRK-GPCR complexes Fergus F. Wallace Professor and Studies Next generation adoptive cell Carolyn R. Bertozzi, PhD with Brian K. Kobilka, MD Chair, Genetics LA JOLLA, CALIFORNIA Nancy A. Speck, PhD therapy: SMARTER T cells for

Yale University School of Investigator, Abramson Family enhanced and durable anti- Kelsie A. Eichel, PhD Jonathan C. Kagan, PhD Christopher P. Lapointe, PhD Medicine Cancer Research Institute tumor immunity with Susan M. Robert A. Swanson Associate Professor, Pediatrics Regulatory roles of the 3’ Howard Hughes Medical Professor and Chair, Cell and Kaech, PhD Family Fellow Harvard Medical School untranslated region in human Institute Scholar Developmental Biology Mechanisms of polarized Shwachman Chair in Thomas H. Mann, PhD* translation with Joseph D. NEW HAVEN, CONNECTICUT University of Pennsylvania membrane protein trafficking Gastroenterology Puglisi, PhD Perelman School of Medicine Calcium signaling and the with Kang Shen, PhD Boston Children’s Hospital PHILADELPHIA, PENNSYLVANIA molecular clock of T cell BOSTON, MASSACHUSETTS exhaustion with Susan M. Kaech, PhD

26 Annual Report 2019 26 27 DAMON RUNYON FELLOWSHIP AWARD CONTINUED

Chuan Li, PhD Albert G. Tsai, MD, PhD§ Jamie Lahvic, PhD Digvijay Singh, PhD* Adam J. Stevens, PhD* Seyed F. Torabi, PhD Connie and Bob Lurie Fellow Diagnosis of hematologic The Mark Foundation for Cryo-electron tomography of HHMI Fellow HHMI Fellow Quantifying epistasis between malignancies from paucicellular Cancer Research Fellow phase-separated transcription Synthetic adhesion molecules: Evolution of triplex-forming tumor suppressor genes aspirate material using highly Uncovering cell non- factories in situ with Elizabeth redirecting cell infiltration and RNAs from random sequences: and revealing the underlying multiplexed single cell analysis autonomous mechanisms of Villa, PhD organization with Wendell A. a search for additional MALAT1- expression profiles at the with Sean C. Bendall, PhD tumor suppression with Iswar K. Lim, PhD like triplex motifs with Joan A. single-cell level in murine lung Hariharan, MBBS, PhD Steitz, PhD University of California, adenocarcinoma with Dmitri A. Jing Lin Xie, PhD Linda T. Vo, PhD San Francisco Petrov, PhD The Mark Foundation for Andrew C. Murley, PhD Off-the-shelf T cells from Illinois Cancer Research Fellow HHMI Fellow Vladislav Belyy, PhD human pluripotent stem cells Fangfei Qu, PhD Remembering the past: Cell non-autonomous Mapping the unfolded protein with precise tumor recognition University of Illinois at Decoding the molecular and epigenetic mechanisms of communication of ER stress response signaling network using combinatorial antigen- Urbana-Champaign cellular mechanisms of the cancer drug resistance with resistance with Andrew G. with optogenetic actuators sensing circuits with Jeffrey A. with Peter Walter, PhD Daniel J. Blair, PhD growth of brain metastases Daniel F. Jarosz, PhD Dillin, PhD Bluestone, PhD Illini 4000 Fellow with Julien Sage, PhD An automated small molecule Leeat Yankielowicz-Keren, PhD Kyle G. Daniels, PhD Lan Wang, PhD University of California, Los Angeles Controlling T cell signaling synthesizer for the discovery Jianjin Shi, PhD Studying the tumor immune Conferring organelle-specificity of new anti-cancer agents with Christina M. Termini, PhD and fate choice using synthetic Layton Family Fellow microenvironment in breast to tail-anchored proteins with Martin D. Burke, MD, PhD Biochemical and genetic cancer using a novel Proteoglycan remodeling receptors with Wendell A. Peter Walter, PhD of the bone marrow niche Lim, PhD dissection of axon degeneration multiplexed imaging platform Sarah Z. Tasker, PhD regulates hematopoietic stem Yichen Xu, PhD with Marc Tessier-Lavigne, PhD with Michael R. Angelo, MD, PhD, HHMI Fellow cell regeneration with John P. Jeffrey A. Hussmann, PhD Elucidating the role of ER as and Edgar G. Engleman, PhD Synthesis and evaluation of a Chute, MD Rebecca Ridley Kry Fellow a novel RNA-binding protein Shaogeng Steven Tang, PhD collection of complex molecules Genome-wide measurement and its function in regulating Merck Fellow biased for penetration of the Toward small-molecule University of California, Berkeley of ribosome spacing on translation with Davide University of California, San Diego blood-brain barrier with Paul J. Allison Didychuk, PhD individual transcripts with Ruggero, PhD inhibitors against human Hergenrother, PhD immune checkpoint PD-1 with The Rhee Family Fellow Richard W. Baker, PhD Carol A. Gross, PhD Peter S. Kim, PhD Viral mimics of host Understanding the mechanisms Dian Yang, PhD transcription factors in of SWI/SNF-mediated Brian J. Laidlaw, PhD Dissecting intratumoral Maryland oncogenic herpesviruses with chromatin remodeling and its HHMI Fellow heterogeneity and hierarchy Britt A. Glaunsinger, PhD misregulation in cancer with Role of EBI2 in the regulation at single cell resolution with Johns Hopkins School of Medicine Andres E. Leschziner, PhD of lymphocyte migration during Jonathan S. Weissman, PhD, Xintong Dong, PhD Stephanie Gates, PhD viral infection and cancer with and Trever G. Bivona, MD, PhD HHMI Fellow HHMI Fellow Janice M. Reimer, PhD* Jason G. Cyster, PhD Investigating ligand-receptor Decoding the ubiquitin receptor Merck Fellow Ziyang Zhang, PhD interactions between defensins recognition mechanism of the Regulation of nucleosome Kara L. McKinley, PhD HHMI Fellow and mrgprs in cutaneous 26S proteasome with Andreas remodelers with Andres E. Mechanisms and functions Controlling the activity of inflammation and wound healing Martin, PhD Leschziner, PhD of cellular rearrangements bispecific T cell engagers with with Xinzhong Dong, PhD in epithelia with Ronald D. a chemically cleavable Vale, PhD molecular switch with Kevan M. Daniel H. Goldman, PhD Shokat, PhD Merck Fellow Trang Nguyen, PhD Elucidating the role of the exon Bypassing the unresponsiveness Xin Zhou, PhD junction complex in regulating “THE DAMON RUNYON FELLOWSHIP ALLOWED ME of T cell anergy and exhaustion Merck Fellow translation of spliced mRNA with Arthur Weiss, MD, PhD Understanding and perturbing with Rachel Green, PhD TO PURSUE PROMISING BUT RISKY QUESTIONS. protein post-translational Jessica Sheu-Gruttadauria, PhD* modifications in cancer and Evan J. Worden, PhD WITHOUT THIS SUPPORT, MY FINDINGS WOULD Probing the dynamic autoimmune diseases with The mechanistic basis of NOT HAVE BEEN POSSIBLE.” organizational network of James A. Wells, PhD crosstalk between histone membraneless organelles H2B ubiquitylation and H3K79 through systems-level analysis Connecticut methylation with Cynthia and imaging with Ronald D. Wolberger, PhD Vale, PhD Yale University Boris Zinshteyn, PhD MATTHEW P. MILLER, PhD Esen Sefik, PhD Sukrit Silas, PhD* HHMI Fellow HHMI Fellow HHMI Fellow Mechanisms of splicing- The effect of microbes and Damon Runyon Fellow ‘14-’18 and Damon Discovery and characterization independent nonsense- diet on the intestinal immune Runyon-Dale F. Frey Breakthrough Scientist ‘18-’19 of virally-encoded translation mediated mRNA decay system in the context of obesity factors with Jonathan S. with Rachel Green, PhD University of Utah Weissman, PhD, and Carol A. with Richard A. Flavell, PhD Gross, PhD

28 29 DAMON RUNYON FELLOWSHIP AWARD CONTINUED

National Institutes of Health Emma V. Watson, PhD Amelia N. Chang, PhD* Deepshika Ramanan, PhD Harvard University Massachusetts General Hospital Suzanne and Bob The role of activity-regulated National Mah Jongg Warakorn Kulalert, PhD Wright Fellow gene expression in human League Fellow Philip B. Abitua, PhD Iva Tchasovnikarova, PhD Characterization of the Metabolic stress response: brain evolution with Michael E. Identifying functions of Developmental mechanisms Deciphering the role of microbiota-mediated cutaneous Exploring transcript-level Greenberg, PhD regulatory T cell subsets of killifish cell dispersion and chromatin remodeling in neuroimmune interface and its regulation of metabolic in intestinal inflammation aggregation with Alexander F. epigenetic repression by the impacts on tumorigenesis and feedback with Stephen J. Anne E. Dodson, PhD and colorectal cancer with Schier, PhD HUSH complex with Robert E. cancer therapy with Yasmine Elledge, PhD Transgenerational inheritance Christophe Benoist, MD, PhD Kingston, PhD Belkaid, PhD of structure-based infections Brian J. Beliveau, PhD with Scott G. Kennedy, PhD Benjamin M. Stinson, PhD HHMI Fellow Kurt J. Warnhoff, PhD Broad Institute Massachusetts Mechanism of DNA processing Decoding Polycomb-mediated Molybdenum cofactor Matthew H. Bakalar, PhD Yuan Gao, PhD* during non-homologous end gene regulation in single biosynthetic enzymes Boston Children’s Hospital Predicting the interactions of HHMI Fellow joining with Johannes C. Walter, cells with single-molecule modulate miRNA biology and super resolution imaging and development with Gary B. Liudmila Andreeva, PhD* T cell receptors with peptide- Mechanism of protein import PhD, and Joseph J. Loparo, PhD synthetic biology with Peng Ruvkun, PhD Making an inflammasome: MHC complexes with Nir into peroxisomes with Tom A. Yin, PhD Structural and biochemical Hacohen, PhD Rapoport, PhD Jonathan G. Van Vranken, PhD* Jingyi Wu, PhD* elucidation of NLRP3 The Mark Foundation for Grace E. Kenney, PhD* Epigenetic clonal evolution in inflammasome activation Ivana Gasic, PhD Cancer Research Fellow Dana-Farber Cancer Institute Merck Fellow gliomas with Bradley Bernstein, with Hao Wu, PhD Merck Fellow Systematic identification of Phillip A. Dumesic, MD, PhD Molecular elucidation of metabolite-protein interactions Two enzymatic routes towards MD, PhD diazo biosynthesis in cytotoxic Megan L. Insco, MD, PhD§ Identification of muscle- the interphase microtubule in human cells with Steven natural products with Emily P. Investigating transcriptional secreted factors responsible integrity response (MIR) with Gygi, PhD Balskus, PhD Massachusetts Institute cyclin dependent kinases as for local and systemic effects Timothy J. Mitchison, PhD of Technology of exercise with Bruce M. Chuchu Zhang, PhD novel melanoma drug targets Alexander M. Jaeger, PhD Spiegelman, PhD Zhejian Ji, PhD Molecular dissection of Area Thomas R. LaBar, PhD* with Leonard I. Zon, MD HHMI Fellow HHMI Fellow Postrema and its role in nausea Elucidating the mechanisms of cellular evolution with Targeting protein folding Aaron L. Moye, PhD* Tikvah K. Hayes, PhD Function of the Cdc48 ATPase in with Stephen D. Liberles, PhD experimental evolution with mechanisms to stimulate anti- Role of Lgr6-expressing David M. Livingston, MD, Fellow protein degradation with Tom A. Andrew W. Murray, PhD tumor immune responses with Mesenchymal cells in lung Systematic genomic and Rapoport, PhD functional analysis of small cell Harvard T.H. Chan School Tyler E. Jacks, PhD cancer initiation and progression of Public Health lung cancer with Matthew L. Lucy Liu, PhD Monica E. McCallum, PhD with Carla Kim, PhD Lindsay M. LaFave, PhD Meyerson, MD, PhD The fat-brain axis: Identifying Jeeyun Chung, PhD Understanding alanosine Investigating epigenetic the roles of adipokine signaling Unraveling the cellular biosynthesis to discover new Esteban A. Orellana mechanisms of transformation Whitney L. Johnson, PhD in nervous system function with mechanism of lipid droplet cancer chemotherapeutics with Vinueza, PhD* in SWI/SNF-mutant non-small Using organoid cancer models Norbert Perrimon, PhD biogenesis with Tobias C. Emily P. Balskus, PhD Role of METTL1-WDR4 tRNA cell lung cancer with Tyler E. methyltransferase complex to identify genome catastrophe Walther, PhD, and Robert V. Christopher Wilson, PhD Jacks, PhD in cancer with Richard I. mechanisms with David S. Nagarajan Nandagopal, PhD Farese Jr., MD Marion Abbe Fellow Gregory, PhD Pellman, MD Philip O’Bryan Montgomery, Jr., MD, Fellow Development of a programmable writer and Yuxiang Zhang, MD, PhD Jasper E. Neggers, PhD* Signal integration by bHLH eraser of m6A RNA methylation HHMI Fellow Validation of VPS4A as a circuits to enable cell fate with David R. Liu, PhD Mechanisms that promote DNA synthetic lethal target in decisions with Sean G. Megason, double strand break clusters in cancers with VPS4B loss on PhD, and Galit Lahav, PhD brain and liver with Frederick W. chromosome 18q with Andrew “I AM CONFIDENT THAT THE KNOWLEDGE AND SKILLS I HAVE Alt, PhD J. Aguirre, MD, PhD, and Natasha M. O’Brown, PhD Todd R. Golub, MD Molecular and cellular GAINED AS A DAMON RUNYON FELLOW HAS PREPARED ME TO Ge Zheng, PhD* mechanisms of transcytosis HHMI Fellow Eric S. Wang, PhD regulation in blood-brain PURSUE MY PASSION TO BE AN INDEPENDENT INVESTIGATOR Novel approaches to targeting Robert Black Fellow barrier function with Sean G. zinc-finger domain of the Enhancing anti-tumor immunity Megason, PhD, and Chenghua IN CANCER BIOLOGY RESEARCH.” transcription repressor BCL11A via pharmacological inhibition Gu, PhD with Stuart Orkin, MD of kinases with Nathanael S. Gray, PhD Sarah J. Pfau, PhD Investigating the molecular Brigham and Women’s Hospital ALLISON N. LAU, PhD Harvard Medical School determinants of blood-brain Kunitoshi Chiba, PhD* barrier heterogeneity with The role of a tumor suppressor Justin A. Bosch, PhD Chenghua Gu, PhD Damon Runyon Fellow ‘15-’19 gene ASXL1 in immune evasion Characterizing novel molecules and mechanisms that mediate during tumorigenesis with Massachusetts Institute of Stephen J. Elledge, PhD cell-cell communication with Norbert Perrimon, PhD Technology

30 31 DAMON RUNYON FELLOWSHIP AWARD CONTINUED

Evan C. Lien, PhD Alexandra Nguyen, PhD* Cornell University Gregory P. Donaldson, PhD* Pennsylvania Lexy von Diezmann, PhD* Impact of diet on tumor Defining the cell type specific Robert Black Fellow The Mark Foundation for Sudeep Banjade, PhD metabolism and progression cell division requirements in Cross-talk between B University of Pennsylvania Cancer Research Fellow with Matthew G. Vander acute myeloid leukemias with HHMI Fellow lymphocytes and bacteria Geoffrey P. Dann, PhD State changes of a liquid- Heiden, MD, PhD Iain M. Cheeseman, PhD Division of labor in ESCRT- in the maintenance of a Merck Fellow like compartment monitor III proteins during polymer non-inflammatory mucosal crossover recombination assembly and membrane Proteomics to bridge protein Jose M. Ordovas-Montanes, PhD Benjamin R. Sabari, PhD microbiome with Daniel arginylation, chromatin, and with Ofer Rog, PhD, and Erik Biomolecular condensates remodeling with Scott D. HHMI Fellow Mucida, PhD cancer with Benjamin A. Jorgensen, PhD Single-cell genomic approaches in normal and diseased gene Emr, PhD Garcia, PhD for tracing the contribution of regulation with Richard A. Yusong R. Guo, PhD inflammation to human colon Young, PhD Washington Memorial Sloan Kettering HHMI Fellow Romain L. Riscal, PhD cancer with Alex K. Shalek, PhD Cancer Center Structural and mechanistic Fructose-1,6 bisphosphatase characterization of Fred Hutchinson Cancer Missouri Harihar Basnet, PhD nuclear localization, new Sharanya Sivanand, PhD* Research Center Identifying determinants of mechanosensitive Piezo functions and implication Understanding metabolic Washington University latency in brain metastatic channels with Roderick in hepatocellular carcinoma Jeremy I. Roop, PhD heterogeneity in primary and MacKinnon, MD Fayez Sarofim Fellow Darryl A. Wesener, PhD breast cancer cells with Joan progression with M. Celeste metastatic tumors with Matthew Defining virus-host co- Synthetic food particles for Massagué, PhD Simon, PhD G. Vander Heiden, MD, PhD Juhee Pae, PhD* evolutionary dynamics that studying human gut microbiota Mechanisms of germinal center underlie the unusually broad function with Jeffrey I. Gordon, MD Jose Reyes, PhD* Peter M.K. Westcott, PhD B Cell proliferation with Gabriel University of Pittsburgh HIV neutralizing antibody HHMI Fellow Exploiting endogenous Dynamics and consequences of D. Victora, PhD Abigail E. Overacre-Delgoffe, response in infants with Julie M. mutational processes in New Jersey complex karyotype evolution PhD* Overbaugh, PhD cancer to enhance response to in p53 driven acute myeloid Linghe Xi, PhD Microbiome control of immunotherapy with Tyler E. Princeton University leukemia with Scott Lowe, PhD, WNT signaling and fate the tumor microenvironment: Ying Qi Shirleen Soh, PhD Jacks, PhD Caroline Bartman, PhD* and Dana Pe’er, PhD specification of normal versus harnessing immunosuppression Mapping paths and mechanisms The Mark Foundation for tumorigenic stem cells with and exhaustion with Timothy W. of virus-host adaptation with Cancer Research Fellow Elaine V. Fuchs, PhD Jesse D. Bloom, PhD Whitehead Institute for Hand, PhD, and Olivera New York University Biomedical Research Systems analysis of in vivo Finn, PhD tumor and stromal cell School of Medicine John C. Zinder, PhD* Tyler Starr, PhD* Laura V. Blanton, PhD metabolism in pancreatic Robert S. Banh, PhD Lorraine W. Egan Fellow HHMI Fellow Lallage Feazel Wall Fellow Texas ductal adenocarcinoma with Merck Fellow Structure and biochemistry of The sequence-function The impact of sex chromosome Joshua Rabinowitz, MD, PhD Metabolic contribution human shelterin and associated landscape of antibody affinity constitution on immune cell University of Texas of sensory neurons, via factors with Titia de Lange, PhD maturation with Jesse D. Bloom, gene expression and function Southwestern Medical Center Andrew A. Bridges, PhD peripheral axons, to pancreatic PhD, and Frederick Matsen, PhD with David C. Page, MD Lindsay B. Case, PhD HHMI Fellow tumorigenesis and serine Weill Cornell Medicine Robert Black Fellow Bacterial cell fates: The role metabolism with Alec Elizabeth Costa, PhD* Regulation of integrin clustering University of Washington of quorum sensing in biofilm Kimmelman, MD, PhD, and Eric E. Gardner, PharmD, PhD Robert Black Fellow on supported lipid bilayers with patterning with Bonnie L. Michael Pacold, MD, PhD Kenneth G. and Elaine A. Yi Yin, PhD Exploring the cell adhesion Bassler, PhD Langone Fellow Michael K. Rosen, PhD Global analysis of DNA break landscape through host- Sophia Tintori, PhD* Interrogating lung repair by single-cell sequencing pathogen interactions with Elise C. Jeffery, PhD Antony J. Burton, PhD Mechanisms of radiation adenocarcinoma transformation with Jay A. Shendure, MD, PhD Sebastian Lourido, PhD Characterizing a new Sculpting chromatin tolerance in to small cell lung cancer at Caenorhabditis hematopoietic stem cell niche architecture in live cells from Chernobyl with Matthew single cell resolution with *Initial Year Nora Kory, PhD factor with Sean J. Morrison, using protein chemistry Rockman, PhD Harold E. Varmus, MD § Physician Scientists HHMI Fellow with Tom W. Muir, PhD PhD Identifying new components Oregon of mitochondrial one-carbon The Rockefeller University New York Utah metabolism with David M. Aleksey Chudnovskiy, PhD Oregon Health & Science University Sabatini, MD, PhD University of Utah School Columbia University Defining dendritic cell-T cell Yunsik Kang, PhD interaction history within the of Medicine J. Brooks Crickard, PhD Molecular mechanisms Daniel H. Lin, PhD tumor microenvironment using Alesia N. McKeown, PhD The Mark Foundation for regulating phagocytosis HHMI Fellow enzymatic labeling with Gabriel HHMI Fellow Cancer Research Fellow of neurons with Marc R. Global influence of mRNA D. Victora, PhD Novel roles for retrogenes Visualizing the strand Freeman, PhD conformation on eukaryotic in host immunity with Nels invasion during homologous translational regulation with C. Elde, PhD, and Cedric recombination on the single David P. Bartel, PhD Feschotte, PhD molecule level with Eric C. Greene, PhD

32 33 DAMON RUNYON-SOHN DAMON RUNYON-SOHN PEDIATRIC CANCER FELLOWSHIP PEDIATRIC CANCER AWARD COMMITTEE FELLOWSHIP AWARD

CHAIR Patrick A. Brown, MD Adolfo A. Ferrando, MD, PhD Director, Pediatric Leukemia Associate Professor, Pediatrics, Andrew L. Kung, MD, PhD Program Pathology and Cell Biology California Massachusetts Srinjoy Chakraborti, PhD Chair and Professor, Pediatrics Associate Professor, Departments Institute for Cancer Genetics Mining pHLA and T cell Memorial Sloan Kettering Zulekha A. Qadeer, PhD* Adam D. Durbin, MD, PhD§ of Oncology and Pediatrics Columbia University Medical receptor (TCR) specificities by Cancer Center Targeting TGF pathway Interrogation of neuroblastoma Johns Hopkins School Center β phage display for de novo TCR NEW YORK, NEW YORK dependencies in Group 3 dependencies and non-coding of Medicine NEW YORK, NEW YORK engineering and personalized Medulloblastoma with William RNAs on the core-regulatory BALTIMORE, MARYLAND Scott A. Armstrong, MD, PhD cancer therapy with Jonathan Lee J. Helman, MD A. Weiss, MD, PhD, University circuitry for therapeutic Chair, Pediatric Oncology R. Lai, PhD, Albert Einstein Peter D. Cole, MD Professor, Departments of of California, San Francisco inhibition with A. Thomas Dana-Farber Cancer Institute College of Medicine, Bronx Professor, Pediatrics Pediatrics and Medicine, Look, MD, Dana-Farber Cancer David G. Nathan Professor Chief, Division of Pediatric Keck School of Medicine Kathryn R. Taylor, PhD Institute, Boston of Pediatrics Marissa Rashkovan, PhD Hematology/Oncology University of Southern The effect of neuronal activity Harvard Medical School Targeting metabolic Embrace Kids Foundation Chair California on pediatric glioma invasion S. Naomi Olsen, PhD Associate Chief of the Division vulnerabilities in ETP-ALL with in Pediatric Hematology/ Head, Basic and Translational with Michelle L. Monje, MD, PhD, Targeted degradation of the of Hematology/Oncology Adolfo A. Ferrando, MD, PhD, Oncology Research, Children’s Center Stanford University School of MLL-AF9 fusion oncoptrotein Boston Children’s Hospital Columbia University Medical Rutgers Cancer Institute of New for Cancer and Blood Diseases Medicine, Stanford in acute myeloid leukemia with BOSTON, MASSACHUSETTS Center, New York Jersey Children’s Hospital Los Angeles Scott A. Armstrong, MD, PhD, Peng Wu, MD, PhD*§ Dana-Farber Cancer Institute, Robert Wood Johnson LOS ANGELES, CALIFORNIA Understanding and modulating Yadira M. Soto-Feliciano, PhD Julia Glade Bender, MD Medical School Boston aberrant differentiation in Dissecting the role of Menin in Vice Chair for Clinical Research Rutgers, The State University Agata Smogorzewska, MD, PhD acute leukemia with C. David hepatoblastoma with Roel Maxim Pimkin, MD, PhD§ Department of Pediatrics of New Jersey Associate Professor and Allis, PhD, The Rockefeller Nusse, PhD, Stanford University, Divergent core transcriptional Memorial Sloan Kettering NEW BRUNSWICK, NEW JERSEY Head, Laboratory of Genome Stanford University, New York Cancer Center Maintenance circuitries highlight context- specific vulnerabilities in AML NEW YORK, NEW YORK The Rockefeller University Tennessee NEW YORK, NEW YORK Maryland with Stuart Orkin, MD, Dana- Farber Cancer Institute, Boston Challice L. Bonifant, MD, PhD§ Katherine E. Gadek, PhD* Dual-antigen targeting by Defining endothelial ENG-T cells as improved anti- New York progenitor cell pliancy in rhabdomyosarcoma with Mark AML therapy with Donald Small, Robert L. Bowman, PhD Hatley, MD, PhD, and Stacey MD, PhD, Johns Hopkins School Interrogating the subclonal Ogden, PhD, St. Jude Children’s of Medicine, Baltimore architecture and functional Research Hospital, Memphis contributions of mutation order Michael A. Koldobskiy, MD, PhD§ in FLT3-ITD mutant AML with “DAMON RUNYON SETS ITSELF APART WITH THE DEPTH DNA methylation stochasticity Ross L. Levine, MD, Memorial Washington in pediatric pre-B cell acute Sloan Kettering Cancer Center, Jay F. Sarthy, MD, PhD§ OF SCIENTIFIC EXPERTISE WITHIN ITS SCIENTISTS lymphoblastic leukemia with New York Characterization of the Andrew P. Feinberg, MD, Johns epigenomic landscape of AND SELECTION COMMITTEES. THIS HELPS YOUNG Hopkins School of Medicine, Jessie A. Brown, PhD* diffuse midline gliomas with Baltimore Candy and William Steven Henikoff, PhD, Fred RESEARCHERS PUSH THE ENVELOPE TO GENERATE Raveis Fellow Hutchinson Cancer Research Cara A. Rabik, MD, PhD§ Master regulators of drug Center, Seattle PARADIGM-SHIFTING DISCOVERIES IN PATIENT CARE Determination of the role of resistance in relapsed acute WT1 in hematopoiesis and lymphoblastic leukemia with *Initial Year AND CANCER BIOLOGY.” leukemogenesis with Patrick Adolfo A. Ferrando, MD, PhD, § Physician Scientists A. Brown, MD, Johns Hopkins Columbia University Medical School of Medicine, Baltimore Center, New York

CHALLICE L. BONIFANT, MD, PhD

Damon Runyon-Sohn Pediatric Cancer Fellow ’16-‘19

Johns Hopkins School of Medicine

34 35 DAMON RUNYON DAMON RUNYON DALE F. FREY AWARD FOR PHYSICIAN-SCIENTIST TRAINING BREAKTHROUGH SCIENTISTS AWARD COMMITTEE

CHAIR Peter S. Nelson, MD Kornelia Polyak, MD, PhD Member, Divisions of Human Professor, Medicine, William G. Kaelin, Jr., MD Brian J. Beliveau, PhD* Sigrid Nachtergaele, PhD* Justin L. Sparks, PhD* Biology, Clinical Research and Medical Oncology Sidney Farber Professor Decoding Polycomb-mediated The dynamic N1-methyladenosine Replicative helicase bypass of Public Health Sciences Dana-Farber Cancer Institute of Medicine gene regulation in single methylome in eukaryotic mRNA bulky DNA lesions at Harvard Endowed Chair for Prostate and Harvard Medical School Dana-Farber Cancer Institute cells with single-molecule at Yale University, New Haven, Medical School, Boston, Cancer Research BOSTON, MASSACHUSETTS and Harvard Medical School super resolution imaging and Connecticut Massachusetts Fred Hutchison Cancer Howard Hughes Medical synthetic biology at University Research Center Jeremy N. Rich, MD Institute Investigator of Washington, Seattle, Thomas M. Norman, PhD* Professor, Medical Oncology Professor, Medicine *Initial Year BOSTON, MASSACHUSETTS Washington Identifying the stochastic Adjunct Professor, Genome Director, Neuro-Oncology determinants of drug resistance Director, Brain Tumor Institute David P. Carbone, MD, PhD Sciences and Pathology at Memorial Sloan Kettering University of California, Tera C. Levin, PhD* Barbara J. Bonner Chair in University of Washington Cancer Center, New York, San Diego Master microbial manipulators: Lung Cancer Research School of Medicine New York SEATTLE, WASHINGTON LA JOLLA, CALIFORNIA how hosts are shaped by Director, James Thoracic Center bacterial interactions at Fred Professor, Division of Medical Alistair B. Russell, PhD* David R. Piwnica-Worms, MD, PhD Cassian Yee, MD Hutchinson Cancer Research Oncology, Comprehensive Impact of heterogeneity on the Professor and Chair, Professor, Melanoma Center, Seattle, Washington Cancer Center cellular recognition of influenza Department of Cancer Medical Oncology The Ohio State University at University of California, Systems Imaging Professor, Immunology, COLUMBUS, OHIO San Diego, California Deputy Division Head, Division of Cancer Medicine Lucy A. Godley, MD, PhD Research Affairs, Division Director, Solid Tumor Cell Co-Director, Center for of Diagnostic Imaging Therapy, Center for Cancer Clinical Cancer Genetics The University of Texas MD Immunology Research Professor, Medicine, Section Anderson Cancer Center The University of Texas MD HOUSTON, TEXAS of Hematology and Oncology Anderson Cancer Center HOUSTON, TEXAS The University of Chicago Medicine CHICAGO, ILLINOIS

“DAMON RUNYON BRINGS TOGETHER THE BEST DAMON RUNYON YOUNG SCIENTISTS OF OUR GENERATION. SUCH A PROFESSIONAL NETWORK WILL HAVE A LONG- PHYSICIAN-SCIENTIST LASTING AND PROFOUND POSITIVE IMPACT ON OUR CAREER DEVELOPMENT.” TRAINING AWARD

California Ashley K. Koegel, MD* Illinois CHAO LU, PhD Engineering next generation Julia C. Carnevale, MD Michael W. Drazer, MD CAR T cells to treat AML: Developing new therapeutic Defining leukomogenic Damon Runyon Fellow ’14-’16 enhancing safety through approaches for pancreatic mechanisms in hereditary and Damon Runyon-Dale F. dynamic control and specificity cancer with homologous hematologic malignancies with Frey Breakthrough Scientist with Wendell A. Lim, PhD, and recombination repair defects Lucy A. Godley, MD, PhD, The ’18-’19 Mignon Loh, MD, University with Alan Ashworth, PhD, University of Chicago Medicine, of California, San Francisco University of California, Chicago Columbia University San Francisco David M. Kurtz, MD, PhD Response prediction and Massachusetts Jennifer L. Caswell-Jin, MD personalized therapy from Breast cancer evolution and Edmond M. Chan, MD* mathematical modeling of resistance in response to HER2- Validating a novel synthetic circulating tumor DNA in non- targeted therapy with Christina lethal target for microsatellite Hodgkin lymphoma with Arash N. Curtis, PhD, and Allison W. unstable cancers with Adam J. A. Alizadeh, MD, PhD, Stanford Kurian, MD, Stanford University Bass, MD, Dana-Farber Cancer University School of Medicine, School of Medicine, Stanford Institute, Boston Stanford

36 37 DAMON RUNYON PHYSICIAN-SCIENTIST TRAINING AWARD CONTINUED DAMON RUNYON CLINICAL INVESTIGATOR AWARD COMMITTEE

Christopher J. Gibson, MD Sakiko Suzuki, MD Melody Smith, MD CHAIR Amato J. Giaccia, PhD Jedd D. Wolchok, MD, PhD Elucidating the connection Inflammatory cell death CD19 targeted donor T cells Jack, Lulu and Sam Willson Lloyd J. Old/Virginia and Daniel Charles L. Sawyers, MD between clonal hematopoiesis pathways in Myelodysplastic improve graft versus tumor Professor in Cancer Biology K. Ludwig Chair in Clinical Chair, Human Oncology and lymphoma in humans with Syndromes with Michelle A. activity and reduce graft Associate Chair for Research Investigation and Pathogenesis Program Benjamin L. Ebert, MD, PhD, Kelliher, PhD, and Peter E. versus host disease with Marcel Director, Division of Radiation Chief, Melanoma and Marie-Josée and Dana-Farber Cancer Institute, Newburger, MD, University of R.M. van den Brink, MD, PhD, and Cancer Biology Immunotherapeutics Service Henry R. Kravis Chair Boston Massachusetts Medical School, Memorial Sloan Kettering Stanford University School Associate Director, Ludwig Memorial Sloan Kettering Worcester Cancer Center, New York of Medicine Center for Cancer Cancer Center Gabriel K. Griffin, MD* STANFORD, CALIFORNIA Director, Parker Institute for Howard Hughes Medical Enhancing cancer Rabi Upadhyay, MD* Cancer Immunotherapy New York Institute Investigator immunotherapy through Determining the distal effects Daniel F. Hayes, MD, FACP, FASCO Memorial Sloan Kettering NEW YORK, NEW YORK epigenetic modulation of the Andrew J. Dunbar, MD* of gut microbiota on the lung Stuart B. Padnos Professor Cancer Center Interrogating functional repetitive genome with Bradley tumor microenvironment, Karla V. Ballman, PhD of Breast Cancer Research NEW YORK, NEW YORK E. Bernstein, MD, PhD, and contribution of JAK2V617F cancer progression, and University of Michigan Rogel in the maintenance of Chief, Division of Biostatistics Arlene H. Sharpe, MD, PhD, checkpoint blockade efficacy and Epidemiology Cancer Center Kwok-Kin Wong, MD, PhD Brigham and Women’s Hospital, myeloproliferative neoplasms with Dan R. Littman, MD, PhD, ANN ARBOR, MICHIGAN Anne Murnick Cogan and with Ross L. Levine, MD, Professor, Healthcare Policy Boston New York University School and Research David H. Cogan Professor Memorial Sloan Kettering Andrew L. Kung, MD, PhD of Medicine, New York Weill Cornell Medicine of Oncology, Department Lillian M. Guenther, MD Cancer Center, New York Chair and Professor, Pediatrics NEW YORK, NEW YORK of Medicine William Raveis Charitable North Carolina Memorial Sloan Kettering Director, Division of John R. Ferrarone, MD Fund Physician-Scientist S. Gail Eckhardt, MD Cancer Center Hematology/Medical Investigation of CITED2 as a Lee Cooperman Nicholas C. DeVito, MD NEW YORK, NEW YORK Oncology, Laura and Isaac Physician-Scientist Investigating the role of Associate Dean, novel dependency in Ewing Cancer Programs Perlmutter Cancer Center sarcoma with Kimberly Seeking and evaluating novel EMT-mediated dendritic cell Ramon E. Parsons, MD, PhD NYU Langone Health therapeutic targets in human tolerization in checkpoint Chair, Oncology Director, Tisch Cancer Institute Stegmaier, MD, Dana-Farber The University of Texas at NEW YORK, NEW YORK Cancer Institute, Boston lung adenocarcinomas with inhibitor resistance with Brent Ward-Coleman Chair, loss-of-function mutations in A. Hanks, MD, PhD, Duke Austin Dell Medical School Cancer Research Director Sandra L. Wong, MD, MS Harshabad Singh, MBBS LKB1 with Harold E. Varmus, University, Durham Professor and Chair, LIVESTRONG Cancer Institutes Chair and Professor, Surgery William Raveis Charitable MD, Weill Cornell Medicine, Oncological Sciences AUSTIN, TEXAS Senior Vice President, Surgical Fund Physician-Scientist New York *Initial Year Icahn School of Medicine Service Line, Dartmouth- Cellular origins of Barrett’s at Mount Sinai Hitchcock Medical Center Jonathan E. Shoag, MD* Howard A. Fine, MD esophagus and its role NEW YORK, NEW YORK The Geisel School of Medicine Harnessing clinical data to Director, Brain Tumor Center in development of at Dartmouth identify new prostate cancer New York-Presbyterian/Weill Stanley R. Riddell, MD adenocarcinoma with Ramesh Cornell Medicine LEBANON, NEW HAMPSHIRE A. Shivdasani, MD, PhD, Dana- therapeutics with Christopher Member, Program in Associate Director, Immunology, Clinical Research Farber Cancer Institute, Boston E. Barbieri, MD, PhD, Weill Founding Member Cornell Medicine, New York Translational Research, Division, Sandra and Edward Meyer Fred Hutchinson Cancer Richard J. O’Reilly, MD Cancer Center Research Center Claire L. Tow Chair, Pediatric Louis and Gertrude Feil Professor, Medicine and Oncology Research Professor of Medicine Oncology Chief, Pediatric Bone Marrow Chief, Division of University of Washington Transplant Service Neuro-Oncology School of Medicine Memorial Sloan Kettering Weill Cornell Medicine SEATTLE, WASHINGTON Cancer Center “WITH DAMON RUNYON SUPPORT, I AM ABLE TO PURSUE MY NEW YORK, NEW YORK NEW YORK, NEW YORK RESEARCH UNFETTERED FOR THE NEXT FEW YEARS WITH SIGNIFICANTLY LESS MEDICAL SCHOOL DEBT, SO I CAN MAKE THE SCIENTIFIC DISCOVERIES THAT WILL HELP PATIENTS.”

LILLIAN M. GUENTHER, MD

Damon Runyon Physician-Scientist ’18-‘22

Dana-Farber Cancer Institute

38 39 DAMON RUNYON CLINICAL INVESTIGATOR AWARD

California Mark G. Shrime, MD, PhD, MPH Adrienne A. Boire, MD, PhD Christopher A. Klebanoff, MD Pennsylvania Texas Cash transfers for cancer William Raveis Charitable Clinical development of next- Collin M. Blakely, MD, PhD Brian C. Capell, MD, PhD David G. McFadden, MD, PhD* surgery in West Africa: Fund Investigator generation T cell receptor Doris Duke-Damon Runyon Defining the role of epigenetic Identifying metabolic their health and economic Molecular determinants of (TCR)-based adoptive Clinical Investigator enhancer dysfunction in vulnerabilities in Hürthle consequences with John G. leptomeningeal metastasis: immunotherapies for the Mechanisms of incomplete epithelial carcinogenesis cell carcinoma with Steven Meara, MD, DMD, MBA, a translational approach with treatment of patients with response and primary with Shelley L. Berger, PhD, L. McKnight, PhD, and Massachusetts Eye and Ear Joan Massagué, PhD, Memorial common epithelial malignancies resistance to osimertinib in University of Pennsylvania, Ralph J. DeBerardinis, MD, Infirmary, Boston Sloan Kettering Cancer Center, with Michel Sadelain, MD, PhD, EGFR-mutant lung cancer with Philadelphia PhD, University of Texas New York and Larry Norton, MD, Memorial Trever G. Bivona, MD, PhD, Southwestern Medical Center, Sloan Kettering Cancer Center, University of California, Jennifer M. Kalish, MD, PhD* Dallas Missouri Karuna Ganesh, MD, PhD* New York San Francisco Epigenetic and genetic Leveraging patient-derived Gavin P. Dunn, MD, PhD mechanisms of cancer organoid models to define Piro Lito, MD, PhD *Initial Year Kavita Y. Sarin, MD, PhD* Characterizing the in Beckwith-Wiedemann the molecular determinants of Modeling the evolution of Genetic contributions and immunogenic landscape Syndrome with Marisa S. metastatic regeneration with resistance to ERK signaling novel therapies for individuals of malignant brain tumors Bartolomei, PhD, and Garrett Joan Massagué, PhD, Memorial inhibitors at the single cell with frequent basal cell cancer Characterizing the immunogenic A. Brodeur, MD, Children’s Sloan Kettering Cancer Center, level with Neal X. Rosen, MD, with Jean Y. Tang, MD, PhD, landscapes of malignant brain Hospital of Philadelphia, New York PhD, and Charles M. Rudin, MD, and Anthony E. Oro, MD, PhD, tumors with John F. DiPersio, Philadelphia PhD, Memorial Sloan Kettering Stanford University School of MD, PhD, and Robert D. Matthew D. Hellmann, MD Cancer Center, New York Medicine, Stanford Schreiber, PhD, Washington University School of Medicine, Defining intratumoral and peripheral mechanisms Catherine C. Smith, MD St. Louis mediating initiation of response, Richard Lumsden durability, and resistance Foundation Investigator DAMON RUNYON to PD-1 blockade to inform Defining structure, function New York rational immunotherapeutic and therapeutic impact of Vinod P. Balachandran, MD development in NSCLC with oncogenic FLT3 mutations William Raveis Charitable Charles M. Rudin, MD, PhD, with Neil P. Shah, MD, PhD, Fund Investigator and Jedd D. Wolchok, MD, CLINICAL INVESTIGATOR AWARD University of California, San Defining the evolutionary PhD, Memorial Sloan Kettering Francisco dynamics and antigen Cancer Center, New York potential of neoantigens for CONTINUATION GRANTS Massachusetts human pancreatic cancer Andrew M. Intlekofer, MD, PhD immunotherapy with Steven Matthew G. Oser, MD, PhD* Metabolic coupling of the D. Leach, MD, and Jedd D. Targeting neuroendocrine hypoxic niche to stemness with Wolchok, MD, PhD, Memorial Illinois Geoffrey R. Oxnard, MD* New York differentiation as a novel Ross L. Levine, MD, Memorial Gordon Family Clinical Sloan Kettering Cancer Center, Jaehyuk Choi, MD, PhD* Christopher E. Barbieri, MD, PhD* therapeutic strategy for small Sloan Kettering Cancer Center, Investigator New York Development of novel Subtype-specific modes cell lung cancer with William G. New York Clinical translation of plasma therapeutic strategies for of clinical and molecular Kaelin, Jr., MD, Dana-Farber cell-free DNA (cfDNA) aggressive CTCL subtypes progression in prostate cancer Cancer Institute, Boston genotyping technologies for with Stephen D. Miller, PhD, with Lewis C. Cantley, PhD, NSCLC care with Pasi A. Janne, and Joan Guitart, MD, Weill Cornell Medicine, New MD, PhD, Dana-Farber Cancer Northwestern University, York Institute, Boston Chicago Heather L. Yeo, MD* “DAMON RUNYON’S FINANCIAL SUPPORT HAS ENABLED ME Eliezer M. Van Allen, MD Use of mobile applications to Massachusetts Dissecting response to evaluate post surgical recovery TO TAKE ACADEMIC RISKS THAT HAVE FORMED THE BASIS conventional and emerging Priscilla K. Brastianos, MD in aging patients with GI cancer DNA damage and repair OF SEVERAL MEANINGFUL AND HIGH-IMPACT DISCOVERIES Investigation of novel targeted with Manish A. Shah, MD, and therapies with Geoffrey I. therapeutic approaches for Deborah L. Estrin, PhD, Weill Shapiro, MD, PhD, Dana-Farber PUBLISHED FROM MY LAB.” brain metastases with Keith Cornell Medicine, New York T. Flaherty, MD, and Tracy T. Cancer Institute, Boston Batchelor, MD, Massachusetts Washington General Hospital, Boston Missouri Aude G. Chapuis, MD Vivek K. Arora, MD, PhD* AMI S. BHATT, MD, PhD Multifaceted transgenic TCR Defining a targetable oncogenic approach to high-risk AML with dyad in bladder cancer with Lee Philip D. Greenberg, MD, Fred Damon Runyon Clinical Ratner, MD, PhD, Washington Hutchinson Cancer Research Investigator ‘16-‘19 University School of Medicine, Center, Seattle St. Louis Stanford University *Initial Year

40 41 DAMON RUNYON-RACHLEFF DAMON RUNYON-RACHLEFF INNOVATION AWARD COMMITTEE INNOVATION AWARD

CO-CHAIR David G. Kirsch, MD, PhD Theodora S. Ross, MD, PhD Massachusetts Alexandra-Chloé Villani, PhD* North Carolina Vice Chair for Basic and Jeanne Ann Plitt Professorship Deciphering the Achilles’ heel Abby F. Dernburg, PhD Eric S. Fischer, PhD Lawrence A. David, PhD, Translational Research in Breast Cancer of cancer immunotherapy Professor, Cell and Novel mechanisms for small and Anthony D. Sung, MD Barbara Levine University H. Ben and Isabelle T. Decherd at Massachusetts General Developmental Biology molecule induced targeted Personalized prebiotics Professor, Radiation Oncology Chair in Internal Medicine, Hospital, Boston University of California, degradation of RRM family to optimize microbiota Professor, Pharmacology Division of Hematology- Berkeley proteins at Dana-Farber Cancer metabolism and improve and Cancer Biology Oncology Biologist, Senior Institute, Boston New York transplant outcomes at Duke Duke University Medical Center University of Texas Faculty Scientist Arnold S. Han, MD, PhD University, Durham DURHAM, NORTH CAROLINA Southwestern Medical Center Lawrence Berkeley DALLAS, TEXAS Joseph D. Mancias, MD, PhD* Precision T cell receptor-based National Laboratory Identifying the pancreatic Richard L. Klemke, PhD cancer therapies at Columbia Ohio Howard Hughes Medical tumor MHC-I ligandome in Professor, Pathology, Julie A. Segre, PhD University, New York Institute Investigator response to ionizing radiation Wayne O. Miles, PhD Moores Cancer Center Chief and Senior Investigator, Maximizing pro-apoptotic BERKELEY, CALIFORNIA for combination radiation- Amaia Lujambio, PhD University of California, Translational and Functional protein levels at The Ohio State immunotherapy at Dana-Farber Overcoming resistance to San Diego Genomics Branch University, Columbus CO-CHAIR Cancer Institute, Boston anti-PD1 immunotherapy in LA JOLLA, CALIFORNIA Head, Microbial Genomics Lewis L. Lanier, PhD Section, National Human hepatocellular carcinoma at Jan P. Schuemann, PhD* Texas American Cancer Society Ivan P. Maillard, MD, PhD Genome Research Institute Icahn School of Medicine at Using extreme dose rates Professor and Chair, Vice Chief for Research, National Institutes of Health Mount Sinai, New York Xiaochun Li, PhD* to protect healthy tissue in Department of Microbiology Division of Hematology- BETHESDA, MARYLAND Investigations on Patched, proton radiation therapy and Immunology Oncology Jason M. Sheltzer, PhD* a tumor suppressor, and at Massachusetts General J. Michael Bishop, MD, Professor, Medicine Stephen T. Smale, PhD Are cancers addicted to its regulation in Hedgehog Hospital, Boston Distinguished Professor Investigator, Abramson Vice Dean for Research, aneuploidy? at Cold Spring pathway at University of Leader, Cancer Immunology Cancer Center David Geffen School of Harbor Laboratory, Cold Texas Southwestern Medical Program, UCSF Helen Diller University of Pennsylvania Medicine at UCLA Spring Harbor Center, Dallas Family Comprehensive Perelman School of Medicine Distinguished Professor, Cancer Center PHILADELPHIA, PENNSYLVANIA Microbiology, Immunology *Initial Year University of California, and Molecular Genetics DAMON RUNYON-RACHLEFF San Francisco Joshua T. Mendell, MD, PhD Sherie L. and Donald G. SAN FRANCISCO, CALIFORNIA Professor and Vice Chair, Morrison Chair, Molecular Department of Molecular Immunology Dafna Bar-Sagi, PhD Biology University of California, Senior Vice President and University of Texas Los Angeles INNOVATION AWARD Vice Dean for Science Southwestern Medical Center LOS ANGELES, CALIFORNIA Chief Scientific Officer Howard Hughes Medical Saul J. Farber Professor of Institute Investigator Benjamin P. Tu, PhD STAGE 2 FUNDING Biochemistry and Molecular DALLAS, TEXAS University of Texas Southwestern Pharmacology Roberto Zoncu, PhD Joseph R. Osborne, MD, PhD Presidential Scholar California Ohio Professor, Medicine Identifying and disabling Chief, Nuclear Medicine and Martha Steiner Professorship Scott J. Dixon, PhD Christin E. Burd, PhD NYU Langone Medical Center organelle circuits that fuel Molecular Imaging in Medical Research Exploring the role of reductive Exploiting mutational NEW YORK, NEW YORK cancer cell metabolism at Director, Molecular Imaging W. W. Caruth, Jr. Scholar stress in promoting cancer cell specificity to target RAS-driven University of California, Innovations Institute in Biomedical Research death at Stanford University, melanoma at The Ohio State Benjamin F. Cravatt, PhD Berkeley Gilula Chair of Chemical Biology Associate Professor, Radiology Professor, Biochemistry Stanford University, Columbus Professor, Chemistry New York-Presbyterian University of Texas Massachusetts The Scripps Research Institute Hospital/Weill Cornell Southwestern Medical Center Rushika M. Perera, PhD* Wisconsin la jolla, california Medicine DALLAS, TEXAS Nadia’s Gift Foundation Marcela V. Maus, MD, PhD* Philip A. Romero, PhD NEW YORK, NEW YORK Innovator Next-generation CAR T cells for Digital circulating tumor Tarun M. Kapoor, PhD Founding Member Mechanisms of cellular EGFRvIII-positive glioblastoma cell detection using scalable Pels Family Professor Nickolas Papadopoulos, PhD transformation at the single at Massachusetts General Professor, Oncology Ronald Levy, MD molecular logic at University Head, Laboratory of Chemistry Robert K. and Helen K. Summy organelle level at University of Hospital, Boston and Cell Biology and Pathology California, San Francisco of Wisconsin, Madison Director of Translational Professor The Rockefeller University New York Genetics, Ludwig Center, Stanford University School *Initial Year NEW YORK, NEW YORK of Medicine Peter J. Turnbaugh, PhD The Sidney Kimmel Nadia’s Gift Foundation Benjamin L. Martin, PhD, and STANFORD, CALIFORNIA Comprehensive Cancer Center Innovator David Q. Matus, PhD* Johns Hopkins University The gut microbiome: an Cell cycle regulation of cellular BALTIMORE, MARYLAND unexpected contributor to behaviors associated with cancer drug resistance at cancer metastasis at Stony University of California, Brook University, Stony Brook San Francisco

42 Annual Report 2019 43 THANK YOU TO EVENTS & BROADWAY TICKETS OUR DONORS

Your support this year enabled us to invest $22.3 million in the next generation of leading scientists tackling the challenges of cancer research with bold new ideas and

innovative technology. 2019 ANNUAL BREAKFAST RUNYON 5K AT YANKEE STADIUM Since our founding in 1946, in partnership with donors Our 2019 Annual Breakfast honoring Board In May 2019, the 11th annual Damon Runyon 5K Member William M. Raveis, Jr., Chairman and at Yankee Stadium drew over 2,100 participants across the nation, Damon Runyon has invested nearly CEO of William Raveis Real Estate, Mortgage and raised more than $415,000. The event $375 million and funded more than 3,750 young scientists. & Insurance, raised more than $1.1 million. was presented by MetLife Foundation, with His tireless commitment to raising funds and additional support from GCT USA, Krasdale, awareness for Damon Runyon has helped Poland Spring, Lifeway Foods, Utz, Cabot, 24 us support scientists pursuing the next Hour Fitness, New York Post, SiriusXM and the breakthroughs against cancer. New York Yankees. DONOR SPOTLIGHT

Thanks to donors like D.G. Mitchell, Damon Runyon has been able to fund brave and bold cancer research that is saving lives. Damon Runyon’s track record demonstrates that our approach works. “Though cancer research has made progress, these efforts are still needed to make safer and more effective therapies for all types of D.G. MITCHELL is a retired cancer. That is why I have named Damon Runyon the largest United Airlines pilot, who has been donating to Damon Runyon beneficiary of my estate,” he says. since 1998.

AWARD SPONSORS RAVEIS RIDE + WALK BROADWAY TICKETS

We are grateful to our individual and corporate sponsors The William Raveis Charitable Fund hosted the Damon Runyon Broadway Tickets offers who have partnered with us to launch new programs or are fourth annual Raveis Ride + Walk in September premium seats to all of Broadway’s hit shows. 2018, raising more than $500,000 for Damon We are grateful to the Shubert Organization, funding one or more of our scientists. Donors can choose to Runyon scientists. The family-friendly fundraiser Nederlander Productions, Jujamcyn Theaters fund scientists based on location, institution, research focus attracts participants from Connecticut, New and Disney Theatrical Productions for making or cancer type, and the award can be named in recognition Jersey and New York. We are grateful to this program possible. Special thanks to our of their gift. For more information, visit: everyone at William Raveis for their partnership Premier Circle members for their ongoing In 2014, GABRIELLE LAYTON, PhD damonrunyon.org/get-involved/sponsor and her husband THOMAS began and support in raising more than $2 million for support of our efforts to end cancer. To supporting the Damon Runyon Layton Damon Runyon since 2015. purchase tickets or gift certificates, please Family Fellows at Stanford. She currently Award sponsors are listed on pages 46–48. visit damonrunyon.org/broadway. serves on the Damon Runyon Board of Directors.

44 45 SPONSORED AWARDS

Andrew C. Murley, PhD LAYTON FAMILY FELLOW Shaogeng Steven Tang, PhD We thank our individual, foundation and corporate sponsors who have partnered University of California, Jianjin Shi, PhD Stanford University with us to launch or provide continuing support for specific award programs. Berkeley Stanford University Xin Zhou, PhD Jose M. Ordovas-Montanes, PhD LORRAINE W. EGAN FELLOW* University of California, Massachusetts Institute of San Francisco Technology John C. Zinder, PhD NATIONAL MAH JONGG HOWARD HUGHES MEDICAL The Rockefeller University DAMON RUNYON-RACHLEFF CLINICAL INVESTIGATOR LEAGUE FELLOW INSTITUTE (HHMI) FELLOWS INNOVATION AWARD CONTINUATION GRANT Jose Reyes, PhD MARION ABBE FELLOW* Sudeep Banjade, PhD Memorial Sloan Kettering Deepshika Ramanan, PhD This award was established Follow-up funding for select Cornell University Cancer Center Christopher Wilson, PhD Harvard Medical School thanks to the vision and Clinical Investigators has been Harvard University generosity of Debbie and provided thanks to the William PHILIP O’BRYAN Esen Sefik, PhD Andy Rachleff. K. Bowes, Jr. Foundation. Brian J. Beliveau, PhD MONTGOMERY, JR., MD, FELLOW Yale School of Medicine THE MARK FOUNDATION FOR Harvard University CANCER RESEARCH FELLOWS Nagarajan Nandagopal, PhD NADIA’S GIFT FOUNDATION GORDON FAMILY CLINICAL INNOVATORS INVESTIGATOR Andrew A. Bridges, PhD Sukrit Silas, PhD Caroline Bartman, PhD Harvard Medical School University of California, Princeton University Rushika M. Perera, PhD Geoffrey R. Oxnard, MD Princeton University San Francisco REBECCA RIDLEY KRY FELLOW* University of California, Dana-Farber Cancer Institute J. Brooks Crickard, PhD San Francisco Christopher J. Cambier, PhD Jeffrey A. Hussmann, PhD Stanford University Tyler Starr, PhD Columbia University University of California, Fred Hutchinson Cancer Peter J. Turnbaugh, PhD FELLOWSHIP AWARD San Francisco Research Center Jamie Lahvic, PhD University of California, Xintong Dong, PhD The following awards are University of California, THE RHEE FAMILY FELLOW San Francisco Johns Hopkins School funded by donors who have Berkeley of Medicine Adam J. Stevens, PhD Allison Didychuk, PhD generously endowed an award University of California, in perpetuity or sponsored an University of California, CLINICAL INVESTIGATOR San Francisco Ariana Peck, PhD individual Fellow. Yuan Gao, PhD Berkeley AWARD Harvard Medical School California Institute of Sarah Z. Tasker, PhD Technology ROBERT A. SWANSON This award was initially CONNIE AND BOB LURIE FELLOW* Stephanie Gates, PhD University of Illinois FAMILY FELLOW established in partnership Chuan Li, PhD Jonathan G. Van Vranken, PhD University of California, Kelsie A. Eichel, PhD with Eli Lilly and Company. In Stanford University Harvard Medical School Berkeley Yuxiang Zhang, MD, PhD Stanford University addition to the named awards, Boston Children’s Hospital DALE F. AND BETTY it is supported by Accelerating Lexy von Diezmann, PhD Cancer Cures, a collaboration ANN FREY FELLOW* Yusong R. Guo, PhD ROBERT BLACK FELLOWS Ziyang Zhang, PhD University of Utah School between Damon Runyon and The Rockefeller University Linghe Xi, PhD University of California, of Medicine Corina E. Antal, PhD leading biopharmaceutical The Rockefeller University San Francisco Salk Institute companies. Alexander M. Jaeger, PhD Massachusetts Institute of Jing Lin Xie, PhD DAVID M. LIVINGSTON, MD, FELLOW Lindsay B. Case, PhD Technology Ge Zheng, PhD Stanford University School RICHARD LUMSDEN FOUNDATION University of Texas CLINICAL INVESTIGATOR Tikvah K. Hayes, PhD Boston Children’s Hospital of Medicine Southwestern Medical Center Dana-Farber Cancer Institute Zhejian Ji, PhD Catherine C. Smith, MD MERCK FELLOWS Harvard Medical School Boris Zinshteyn, PhD University of California, DENNIS AND MARSHA Elizabeth Costa, PhD Johns Hopkins School Robert S. Banh, PhD San Francisco DAMMERMAN FELLOW* Whitehead Institute for of Medicine New York University School Nora Kory, PhD Biomedical Research WILLIAM RAVEIS CHARITABLE Marsha M. Hirschi, PhD Whitehead Institute for of Medicine FUND CLINICAL INVESTIGATORS Scripps Research Institute Biomedical Research ILLINI 4000 FELLOW Gregory P. Donaldson, PhD Daniel J. Blair, PhD Geoffrey P. Dann, PhD Vinod P. Balachandran, MD FAYEZ SAROFIM FELLOW* The Rockefeller University Memorial Sloan Kettering Brian J. Laidlaw, PhD University of Illinois University of Pennsylvania Jeremy I. Roop, PhD University of California, Cancer Center Seyed F. Torabi, PhD Fred Hutchinson Cancer San Francisco KENNETH G. AND ELAINE A. Ivana Gasic, PhD LANGONE FELLOW* Yale School of Medicine Adrienne A. Boire, MD, PhD Research Center Harvard Medical School Daniel H. Lin, PhD Memorial Sloan Kettering Eric E. Gardner, PharmD, PhD Eric S. Wang, PhD FRATERNAL ORDER OF Whitehead Institute for Weill Cornell Medicine Daniel H. Goldman, PhD Cancer Center EAGLES FELLOW* Dana-Farber Cancer Institute Biomedical Research Johns Hopkins School LALLAGE FEAZEL WALL FELLOW* Victoria Hung, PhD of Medicine SUZANNE AND BOB WRIGHT FELLOW* Stanford University Alesia N. McKeown, PhD Laura V. Blanton, PhD Emma V. Watson, PhD University of Utah School Whitehead Institute for Grace E. Kenney, PhD Brigham and Women’s Hospital of Medicine Biomedical Research Harvard University

Janice M. Reimer, PhD University of California, San Diego 46 47 SPONSORED AWARDS CONTINUED OUR CONTRIBUTORS

DAMON RUNYON-SOHN Cara A. Rabik, MD, PhD WILLIAM RAVEIS CHARITABLE FUND PHYSICIAN-SCIENTISTS PEDIATRIC CANCER Johns Hopkins University The Damon Runyon Cancer Research Foundation acknowledges the generosity of the FELLOWSHIP AWARD Lillian M. Guenther, MD many donors who supported our brilliant researchers through gifts to the Foundation from Marissa Rashkovan, PhD Dana-Farber Cancer Institute This award program was Columbia University July 1, 2018 to June 30, 2019. Individuals whose lifetime giving is $100,000 or more are launched in partnership with Medical Center Harshabad Singh, MBBS the generous support of the listed in bold, and those whose lifetime giving exceeds $1 million are listed in blue. We Dana-Farber Cancer Institute Sohn Conference Foundation. Jay F. Sarthy, MD, PhD are especially grateful to these extraordinarily generous and committed donors.

CANDY AND WILLIAM RAVEIS FELLOW Fred Hutchinson Cancer Research Center DAMON RUNYON-JAKE Jessie A. Brown, PhD WETCHLER AWARD FOR Kathryn R. Taylor, PhD PEDIATRIC INNOVATION Columbia University Karen D. Seitz Stanford University School $1,000,000+ $50,000 - $99,999 Medical Center This $5,000 award is named in of Medicine Connie and Bob Lurie AbbVie, Inc. The Richard C. and Theresa P. honor of Jake Wetchler, who Smith Memorial Fund DAMON RUNYON-SOHN PEDIATRIC The Mark Foundation Amgen, Inc. died at age 20 after a heroic Cynthia F. Sulzberger CANCER FELLOWS SUPPORTED Peng Wu, MD, PhD for Cancer Research fight against two different Angelo Gordon and Steven B. Green BY THE SOHN CONFERENCE Stanford University FOUNDATION cancers. Anonymous $500,000 - $999,999 Sol and Margaret Berger Challice L. Bonifant, MD, PhD $10,000 - $24,999 Challice L. Bonifant, MD, PhD Foundation Johns Hopkins School DAMON RUNYON PHYSICIAN- William K. Bowes, Jr. Johns Hopkins School Edith C. Blum Foundation Baupost Group, LLC of Medicine SCIENTIST TRAINING AWARD Foundation of Medicine Merck & Company, Inc. Equinix, Inc. Nancy and Lawrence Bossidy This award was established Gilead Sciences Janet and Richard Bruce Adam D. Durbin, MD, PhD William Raveis Charitable Fund thanks to the generosity of *In perpetuity Hettinger Foundation Joyce and Ronald A. Castellino, MD Dana-Farber Cancer Institute Sohn Conference Foundation Damon Runyon Board Members Illini 4000 Corcept Therapeutics Leon G. Cooperman and National Mah Jongg League Michael A. Koldobskiy, MD, PhD Echlin Foundation Michael L. Gordon. $100,000 - $499,999 Foundation Johns Hopkins University Lorraine and Bill Egan Anonymous Candy and Bill Raveis LEE COOPERMAN Ensemble Capital, LLC Select Equity Group Zulekha A. Qadeer, PhD PHYSICIAN-SCIENTIST The Bakewell Foundation The Ettl Family Philanthropic Barthold Family Foundation Foundation Fund University of California, John R. Ferrarone, MD Terry and David Beirne Edward P. Evans Foundation San Francisco Weill Cornell Medicine Robert Black Charitable $25,000 - $49,999 Facebook Foundation Judy Hart Angelo Paula and James Gould Estate of Adrienne and Harry Anonymous Joan Lobis Brown and Chamberlain Jeremy Grayzel Beacon Capital Partners, LLC Deborah J. Coleman and Sharon and Scott Greenstein Robyn and Tony Coles, MD Timothy W. Diggins Hanna Family Fund Estate of Rita Eisenberg The Leon and Toby Cooperman Estate of Irma T. Hirschl Family Foundation The Erlbaum Family Steven A. Kandarian Eli Lilly and Company Glover Acquisitions, LLC Elaine and Kenneth Langone Genentech, Inc. Grand Aerie Fraternal Order The Layton Family Fund Michael L. Gordon of Eagles The Lichtenberger Foundation Howard Hughes Medical Estate of Terence P. Haskins “OUR INVESTMENT IS TARGETED TO A SPECIFIC Institute Steve Hayden McKesson Corporation Sherry and Alan Leventhal Valerie and Jay Ireland Carole Middleton Fund RESEARCHER, WORKING ON A SPECIFIC PROJECT. Family Foundation Morana Jovan-Embiricos, PhD Jody and John Myers Richard A. Lumsden Katherine and Henry Mannix III Linda and Max R. Proffitt, PhD OUR ENTIRE FAMILY FEELS CONNECTED TO THESE Foundation Sandy and David Marshall Pyramid Hotel Group MetLife Foundation Susan Riley and John McKeown Louis and Rachel Rudin SCIENTISTS.” Foundation, Inc. Nadia’s Gift Foundation Gordon H. and Karen M. Millner Novartis Family Foundation Schulte Roth & Zabel LLP Debbie and Andy Rachleff D.G. Mitchell Paula Ryan, MD, PhD, and Michael Seiden, MD, PhD GABRIELLE LAYTON, PhD Isabel and In Sik Rhee Mary and Eugene F. Murphy Judy C. Swanson Henry J. and Kathleen Singer The Frances and Abraham Family Foundation Damon Runyon Board Member Anita Tarr Turk Fund for Breast Reichman Charitable Trust Cancer Research The Linda B. and Howard S. The Bruce Robert Reid Family Stern Family Foundation Laura and Peter Van Camp Foundation The Swig Foundation The Rogers Charitable Fund The Symonds Foundation

48 49 OUR CONTRIBUTORS CONTINUED

Polly Tam and Hsien-Chung Woo Friedman Family Foundation The Leo Model Foundation, Inc. Carole and Jerry Turk Family Bonnie Carpenter Adam Friedman Carol and Lee Tesconi GCT USA M.P.O., Inc. Philanthropic Fund Thomas Carrajat Phyllis and Guy Fritts Tzedakah Foundation General Electric Foundation People’s United Bank, N.A. The Wasserman Foundation Edward and May Yee Chan Elaine V. Fuchs, PhD, and David Peter J. Worth Genomic Health Julie and James Pulk Waterfall Family Foundation Memorial Fund Hansen Erica Evans Gioffre and Michael Bob Raiff Barbara and Robert Young Julia Espel and Kenneth Chang Paul Fulton Gioffre Charina Foundation Robert Furr $5,000 - $9,999 Emily and Michael Repperger The Walter F. and Alice Girham Sylvia and Norman Samet $1,000 - $4,999 Judy Chase Gabelli Funds Anonymous (2) Foundation, Inc. Gary M. Saretsky Janice and Gary H. Cherrier Stephanie Galbreath Atlassian Barbara and Jerome Ackerman Marcia and John D. Goldman Marvin C. Schwartz Elizabeth M. Christiansen Robert W. Garthwait, Sr. Barbara Lieb Baumstein Carolyn Aller Heitman, LLC Estate of Maude B. Seifert John T.J. Coe Nancy and Richard B. Gaynor, MD The Howard Bayne Fund Sharman and David Altshuler Joan and Robert M. Hess Felice Shea Cynthia and Jay L. Cohan Jean and Robert Gibson, Jr. Jill C. Bee Advised Fund Lori and Wayne Hummel Suzy Sang Shechtman Charitable Gift Fund Jeffrey W. Glazer Foundation Isabel and Steven Berg Ambrose & Strazza, LLC Andre Hunter Gerri and Andrew Sommers Paula and Martin Cohen Alfred S. Glazier The Chubb Corporation Mary and Roy Anderson Julie A. Kane Robie and John Spector Charitable Foundation Melissa L. Cohn Joseph Gleberman Estate of Laurelia M. Clifford Angela and Noah Knauf State Street Global Advisors Anonymous (3) Harvey Coleman Ken Globus Estate of Alice E. Conover Richard A. Konigsberg Stewart Senter, Inc. The Apple Lane Foundation Lorrie and Robert N. Cooney, MD Steve Goldberg Helga and Frank Doyle Clare and Kenneth Livak, PhD Barbara and Peter Strauss Cheryl Bacharach Kristine and Jonathan Crawford Paul D. Goldenheim Jane and Larry Droppa Jackie Lowey Philanthropic Fund Ellen and Henry Baer Jennifer Daley Goldie Anna Charitable Trust Estate of Edward and Stephen Lowey Suhler Family Fund Dorothy D’Amato Goldman, Sachs & Co. Matching Bozena Etnyre Susannah Bailin The Luppe And Paula Luppen Jennifer Toll Bamberger Polymers Lawrence H. David Gift Program The Frances and Jeffrey Fisher Family Foundation TPG Global, LLC Richard Barnett Richard Day Lawrence Goldrich Charitable Foundation Caryn and James I. Magid The Barron Family Charitable Steven DeCillis II Mitchell Goldstein Giving Fund Doreen and Michael Carl Golub Tim Barton DeDomenico Martha and Todd R. Golub, MD Eslyn and Richard Bassuk Colleen Delaney, MD, MSc Paul Goodman A. Patricia and Gerritt M. Bates Herb Deuschel Grabe Family Foundation F. Harlan Batrus Peggy and Phil DeZwirek Elizabeth A. Gray Debra and Marc Bennet Diao Family Foundation Efraim Grinberg “I RESEARCH CHARITIES THAT I AM James Bennett Nicholas Didycz Mignon Groch Ann and Thomas Berger Gayle and John Dilley Terri Grodzicker, PhD CONSIDERING VERY CAREFULLY. WITH Sandye Berger Derek Dolney Annie Gross The Len and Laura Berlik Elizabeth Donahue Eric Gross DAMON RUNYON, I AM RELIEVED THAT Foundation, Inc. James Dow Kristy and Robert L. Harteveldt Jordan Berman John Dunham Philip J. Harvey I DON’T HAVE TO DIG DEEPER BECAUSE Edgar Berner Family Fund Jennifer Eddington Happy G. Hawn of the Jewish Community Liza and William Edgerton Healey Family Foundation EVERY DOLLAR GOES TO CANCER Foundation Negin Etemad Kathi and Bill Heater Eugenie and Robert Birch Dorothy and Robert Eveleigh Darren Henault Mindee Blanco RESEARCH.” Marilyn and Erwin Ezzes Jane and R. Lee Hite BLL Foundation Eleanor and Thomas J. Harriet and Ashley Hoffman William Boeh Fahey, Jr., MD Lisa Gross and Richard Hoffman Joyce and Eugene K. Bolton Farella Braun & Martel LLP Sandra Horbach and Steven Donna Boone Jody Fay Skoler June and Thomas Bracken Phyllis and Samuel Feder The Harold and Ethel Horowitz Perry Brandt Roberta Fine Family Charitable Foundation MARTIN J. COHEN Renier J. Brentjens, MD, PhD Nancy A. Federspiel, PhD, and Celia Pohani and Daniel Huber Donald F. Brown Robert F. Fisher, PhD Scott R. Isdaner Jill and Mark Fishman Discovery Society Member Judy Buechner Advised Fund Tyler E. Jacks, PhD Ann and Frank Bumstead Thomas Florkowski Robert D. Jaffee Suzanne and Steven J. Elisabeth Fox J.I. Foundation, Inc. Burakoff, MD Fraenkel Charitable Fund Edwina C. Johnson Burlingame Foundation Amy Francis, PhD Johnson-Miller Foundation Nancy S. Calcagnini Fund Amy and Wendy Franklin-Willis JPMorgan Chase Foundation Yvette Calderon Kelly and Buck French William G. Kaelin, Jr., MD The Calf Island Foundation Mary Ann Frenzel Gregory Kahlert CancerHealth.com Otto N. Frenzel III Silky Kamdar

50 51 OUR CONTRIBUTORS CONTINUED

Howard Kaneff MB Real Estate Peter Rosenberg Clay K. Surovek Ultimate Software Group, Inc. Judith Z. Weinberg Ed and Ann Kania Foundation Christopher McGarrigal Judy Rosenblum Lisa Szubin University of Dayton David and Candace Weir Robert Kaplan David McIntosh Maddy Ross Karen and Sanford Teplitzky Marilyn and Scott Urdang Foundation The Shelly and Michael Kassen Jami W. McKeon The Roxe Foundation Patricia and J. Ronald Mary Vance Carol Windsor and James A. Philanthropic Fund Colleen and Michael W. Kimberly Rubin Terwilliger Ruth Vanover Wells, PhD Paul M. Katz McMahon Gregory Rush Panayiota and Ilias Dana Vargas-Lurie Robin M. West Eric Keisman, PhD David George McMillan Daniel Sack Theodoropoulos Craig M. Varrelman, CFA Janet M. and Alan Widra Ellen Kerr John McStay Barbara A. and Richard L. Tullia Lindsten, MD, PhD, and Edward Wacks Lief Sannen and Lawrence Craig Thompson, MD Wieman Diane Kilroy Martin Metz Sanderson Robert T. Waldbauer, Jr. Barbara Corwin Timken Winfield Foundation Jennifer and James H. Kimenker Fred Middleton Shamba Sandy Jean H. and John T. Douglas Kinney Suzy, Nancy, and Carol Minkoff Albert Santos Jennifer and Don Torey Walter, Jr. Fund Jami McLaughlin and Owen N. Witte, MD Stephanie Kinsman Charitable Fund Linda and Jerry Saslow Townhouse Management Michele and Donald Weeden Company Rod Wood Lisa F. Kirkpatrick Kathy and Russ Mitchell Cary M. Schwartz Helene and Stephen Weicholz Daniel Tracy Gayle and Emmett Zimmerman III Lee P. Klingenstein Richard C. Moore, Jr. Eugene P. Schwartz Family Joanne and Arthur Weinbach Jane Turley Seymour W. Zises Frank T. Koelble Kelly Moresi Foundation Judith Konigsberg Patty Hogan and Sanford Harry A. and Joseph Schwartz Dorothy R. Davies and Jeremy Morhouse Family Foundation R. Kramer Linda and Kevin Mullane Barbara and Robert D. Scinto Krasdale Foods Muffie Bancroft and W. Stephen William Scroggins Sandra Krause Murray Carla and Richard Scudellari Wendy Kreeger Herbert Natof, MD Marianne and William Sellers, MD The Krimendahl/Saint-Amand Alison and James Neisloss Ethel G. Sensenig Foundation Neu Foundation of California, Inc. Rita Sherr The Kugler Foundation Sonia and Phillip Newmark, PhD Lois Sherwin Barbara and W. Loeber Landau Randolph Ney Mindy and Robert Sherwin Elizabeth Landes Sanford J. Nusbaum Geetanjali and Ramesh A. Ellen S. Lane Paula Oppenheim Shivdasani, MD, PhD Janice R. Lane Marty Osborn The Sidewater Family Cynthia and Ned C. Lautenbach Jeffrey M. Ostrove, PhD Foundation, Inc. “AS FUNDING FROM TRADITIONAL SOURCES Jasbeena and Ralph Layman Pace Plumbing Corporation Karina A. Litvack and Clifford A. Siegel Fabienne Lecole Donna and Chris Paisley Karen and Harvey Silverman CONTINUES TO SHRINK, THE IMPACT OF Tova Leidesdorf Palisade Capital Management Shelly M. Payne, PhD Joann and Samuel C. Grace Leone Silverstein, MD Agnes Peelle Levin Capital Strategies, LP Nancy Simonian, MD FUNDING FROM DAMON RUNYON GROWS Robert M. Pennoyer Daniel Levy Gayle Slate Pfizer Foundation Stephen M. Levy Trudy and Fredric C. Slater IN IMPORTANCE. EXPANDED SUPPORT Joseph Piorkowski David Lewis Eric Small Vickie and Rahn Pitzer Estate of Franklin S. Lewis Jeff Smith Helen M. Piwnica-Worms, PhD, FOR EARLY-STAGE SCIENTISTS IS KEY TO Laura Linsmeier Estate of Lidie Anne Smith Susan and Martin Lipton and David R. Piwnica-Worms, MD, PhD Estate of Mildred A. Smith Emily and David Livingston, MD MAXIMIZING NOVEL DISCOVERIES AND Louis Popowsky Irene Smolicz Michael Lorusso Elizabeth and Tim Portland Anne Sneed Frank E. and Miriam Loveman Susan L. Solomon MAJOR BREAKTHROUGHS.” Foundation, Inc. Elizabeth Portland and Thomas Toce Jonathan Sonneborn Loynd Family Foundation Ronnie Potter Philippe Soriano, DSc, PhD Hua Lu, MD, PhD Rick Powell Teresa and Kenneth Stabler Abigail and Case Lynch Lee Pressler Patricia and James Staley Jean and Michael J. Maher GORDON RINGOLD, PhD Michael E. Rachlin Keren and Alex Stankevich Marble Fund, Inc. Deborah and Lawrence Raiman Bob Stefanowski Julie and Gerald Marshall Damon Runyon Fellow ’77-‘78 RBC Capital Markets Kenneth L. Stein Maryland Charity Campaign and Bay Area Committee Corporation Bruce W. Stillman, PhD, FRS William Matthews Member Joan F. and John M. Regan Sybil and Adam Strum Roger A. May Paula Robichaud Judith Studer Chief Executive Officer, Helen and Tom May Rockefeller Financial Services, Inc. Mark Stueve Quadriga Biosciences Theodore and Karin Mayer Karen and Gary Rockhold Family Foundation Martin J. Sullivan Barbara Rodriguez

52 53 ACCELERATING CANCER CURES BROADWAY PREMIER CIRCLE

Accelerating Cancer Cures is supported by leading biopharmaceutical companies The Broadway Premier Circle is a group of loyal Damon Runyon Broadway Tickets that are committed to finding new cures for cancer. Thank you to Eli Lilly and Company, customers who have made a special donation in support of cancer research. The Genentech, Merck, AbbVie, Amgen, Gilead and Novartis for partnering with us to Premier Circle offers members priority access to tickets and other benefits. support the Damon Runyon Clinical Investigator Award. David Altshuler Scott R. Isdaner Sylvia and Norman Samet In conjunction with this initiative, each year the Accelerating Cancer Cures Research Susannah Bailin Julie A. Kane Linda and Jerry Saslow Jill C. Bee Robert Kaplan David G. Schwartz Symposium brings together our Clinical Investigators with industry leaders to foster Julia and Edgar F. Berner Jennifer and James H. Kimenker Eugene P. Schwartz Family communication and collaboration helping speed progress against cancer. Eugenie and Robert Birch Richard A. Konigsberg Foundation Janet and Richard E. Bruce Dorothy R. Davies and Jeremy Felice Shea Elizabeth M. Christiansen R. Kramer Rita Sherr Samuel T. Cohen Grace Leone Lois Sherwin Dorothy D’Amato Marcia and William Levy The Sidewater Family Jane and Larry Droppa Stephen M. Levy Foundation, Inc. Liza and William Edgerton Susan and Martin Lipton Charlotte and John S. Suhler Marian and Robert Ettl Clare and Kenneth Livak, PhD J. Ronald Terwilliger Jill and Mark Fishman William M. Matthews Jennifer Toll Mary Ann Frenzel Colleen and Michael W. Edward Wacks Jeffrey W. Glazer Foundation McMahon Judith and Peter Wasserman Paul D. Goldenheim Nancy and Russell C. Minkoff Susan Waterfall Joan Lobis Brown and Jeremy Agnes Peelle Helene and Stephen Weicholz Grayzel Paula Robichaud Janet M. and Alan Widra Efraim Grinberg Judy Rosenblum Jami McLaughlin and Owen N. Mignon Groch Joseph D. Roxe Witte, MD Andre Hunter Kimberly Rubin Barbara and Robert C. Young, MD

“FOR THE YEARS I’VE BEEN AN ADVISOR TO DISCOVERY SOCIETY DAMON RUNYON, I’VE SEEN HOW MANY YOUNG

RESEARCHERS HAVE GONE ON TO BECOME Discovery Society members are valued supporters who have provided for the Damon LEADERS IN THE FIELD AND ARE BEHIND Runyon Cancer Research Foundation through future planned gifts. These donations provide a vital source of support and fuel future breakthroughs against cancer. SOME OF THE KEY DISCOVERIES IN THE FIGHT Elaine M. Addis Mary Ann Frenzel Lynne and Rick Robinson AGAINST CANCER.” Anne C. Burkholder, PhD, and Nancy and Richard B. Gaynor, MD Seymour Rosenheck Stephen P. Eisenberg, PhD Rick J. Govern Esther E. and Herbert Schwartz Judy Chase Georgia M. and William C. Hines William Scroggins Paula and Martin Cohen Rebecca R. Kry Phoebe Showers NANCY VALENTE, MD Toby and Leon Cooperman Linda B. Lloyd and Lewis L. Wallace Specter Ann K. Cote Lanier, PhD Carol H. Stix Senior Vice President, Phyllis Farleigh Catherine and Leo LoFrisco Rose Vaccariello Genentech Nancy A. Federspiel, PhD, and D.G. Mitchell Jacqueline and Arthur Walker Robert F. Fisher, PhD Debra L. and Ronald E. Parr

54 55 WAYS FINANCIAL SUMMARY TO GIVE FISCAL YEAR 2019 As in previous years, the financial activities of the Damon Runyon Cancer Research Foundation were audited by RMS US LLP. Below is a snapshot of FY2019.

For our complete audited financial statements, please visit our website at ONLINE damonrunyon.org damonrunyon.org/donate

TOTAL OPERATING EXPENSES TOTAL REVENUE PHONE 1.877.7CANCER or 1.877.722.6237 9 am–5 pm ET, Monday to Friday

MAIL $26 $26 One Exchange Plaza, 55 Broadway, Suite 302 MILLION MILLION New York, NY 10006

ESTATE PLANNING

Visit our website for more information: Award Programs 85.4% Investment Return 51.9% damonrunyon.org/get-involved Fundraising 11.6% Contributions 40.9% General Administration 3.0% Misc. Income 4.3% Bequests & Trusts 1.5% Damon Runyon Broadway Tickets 1.4% DAMON RUNYON BROADWAY TICKETS Damon Runyon Broadway Tickets offers Broadway’s best seats and the opportunity to support cutting-edge cancer research at the same time. Orchestra seats are available for even the most popular shows. 2018 2019 SUMMARY OF Total Assets $148,707,992 $150,535,887

Join our Premier Circle to Our Gift Certificates are Call us for tickets at BALANCE SHEETS Total Liabilities $32,236,227 $35,517,843 enjoy benefits like priority perfect for holiday gifts, as 212.455.0550 between Total Net Assets $116,471,765 $115,018,044 access to tickets before well as birthdays, anniversaries, 9 am–5 pm ET, Monday they go on sale each month, or any occasion—a fun night to Friday. Purchase tickets and more. and a meaningful gift. online at damonrunyon.org/ broadway 100% OF YOUR DONATION FUNDS BRILLIANT SCIENTISTS. We pay our low overhead with revenue from Damon Runyon Broadway Tickets and our endowment.

56 57 100% OF YOUR DONATION FUNDS BRILLIANT SCIENTISTS.